



Supplementary Information for
Chirality-Matched Catalyst-Controlled Macrocyclization Reactions

Jaeyeon Hwang^a, Brandon, Q. Mercado^a, Scott J. Miller^{a*}

^aDepartment of Chemistry, Yale University, P.O. Box 208107, New Haven, Connecticut 06520-8107, United States

corresponding author: Scott J. Miller*

Email: scott.miller@yale.edu

This PDF file includes:

Supplementary text
Figures S1 to S4
Tables S1 to S4
SI References

Table of Contents

1. General Information.....	3
1.1 Abbreviation	5
2. Synthesis of Guanidinylated Amino Acid Ligands	6
3. Synthesis of Diarylmethane	6
4. Synthesis of Bifunctional Nucleophiles.....	6
4.1 General Synthetic Routes for Bifunctional Nucleophiles:.....	6
4.2 General Procedure 1: Sonogashira Coupling.....	6
4.3 General Procedure 2: Acylation of Alcohols.....	7
4.4 General Procedure 3: Hydrogenolysis & Nitro Reduction	7
5. Characterization and Spectra of Bifunctional Nucleophiles and Intermediates	7
5.1 Cross-coupled Products	7
5.2 Acylation Products.....	10
5.3 Hydrogenolysis Products: Bifunctional Nucleophiles	13
6. Synthesis of Aminophenol 2f.....	37
6.1 General Synthetic Route to 2f.....	37
6.2 Characterization of Aminophenol 2f and Intermediates.....	37
7. Bimolecular Competition Experiments: Determination of Chemoselectivity	44
7.1 Table S1. Bimolecular competition experiments ^a	45
8. Procedures for Cu-catalyzed Intermolecular C–C Coupling	45
8.1 Procedure 4: Cu-catalyzed Intramolecular C–C Coupling with an Achiral Ligand.....	45
8.2 Procedure 5: Preparation of Enantioenriched Diarylmethanes by C–C Coupling..	46
8.3 Procedure 6: TBS Deprotection en route to Aminophenol 3f.....	46
8.4 Characterization and Spectra of Linear Precursors.....	48
8.5 HPLC Traces of Linear Precursors (3a-3f).....	88
9. Reaction Optimizations and Procedures for Macrocyclization via Cu-catalyzed intramolecular C–N cross-coupling	92
9.1 Procedure 7: Protocols for Small-Scale Intramolecular Ullmann cross-coupling..	92
Figure S1. Sample of Determination of NMR yield.....	93
9.2 Identification of Optimal Model Substrates ^{a,b,c}	93
9.3 Table S2: Cu(I) Screen.....	94
9.4 Table S3: Concentration Effects	94
9.5 Table S4: Temperature & Copper Loading	95
10. Procedure 8: Macrocyclization of Diarylmethanes Under Optimized Conditions	96
11. Kinetic Resolution of Diarylmethanes Under Optimized Conditions	96
12. Characterization and Spectra of Macrocyclic Products (4a-4f, 5f).....	98
12.1 HPLC Traces of Macrocyclic Compounds (4a-f).....	127
13. Product Distribution: Macrocyclization of 3a, 3b and 3c (UPLC-MS Traces)	133
14. Product Distribution: Macrocyclization of Aminophenol 3f (UPLC-MS Traces) ...	134
15. NMR Studies.....	136
15.1 VT-NMR Experiments ^{a,b,c}	136
15.2 Deuterium Incorporation in Methanol-d ₄ :	138
15.3 ¹ H NMR Spectra of 4a in Different NMR Solvents	139
16. Crystallographic Data	142

1. General Information

Room temperature is defined as 21–25 °C. The following reagents, CuBr (99.998%, STREM), CuI (99.998%, STREM), Cu(MeCN)₄BF₄ (>98%, TCI America), Cs₂CO₃ (99.9%, Sigma-Aldrich) and K₃PO₄ (99.9%, Sigma-Aldrich) were purchased from the corresponding commercial suppliers and used as received. All other reagents were purchased from commercial suppliers and used without further purification, unless otherwise noted. Acetonitrile, *N,N*-dimethylformamide, toluene and tetrahydrofuran were obtained from a Seca Solvent System by GlassContour, in which the solvent was dried over alumina and dispensed under an atmosphere of Ar. Triethylamine (Et₃N), *N,N*-diisopropyl ethylamine (ⁱPr₂NEt) and pyridine were distilled over CaH₂ under a nitrogen atmosphere prior to use. All other solvents were purchased from commercial suppliers and used without further purification, unless otherwise noted.

Routine ¹H NMR spectra were recorded on Agilent 400, 500, or 600 MHz spectrometers at ambient temperature unless otherwise stated. All NMR solvents were purchased from Cambridge Isotope Laboratories and used without further purification. Chloroform-*d*, dichloromethane-*d*₂, acetone-*d*₆, acetonitrile-*d*₃, and deuterium oxide-*d*₂ were stored at ambient temperature, and methanol-*d*₄ and dimethylsulfoxide-*d*₆ ampoules were used immediately after opening. Spectra were processed using MestReNova 14.2.0 using the automatic phasing and polynomial baseline correction capabilities. Splitting was determined using the automatic multiplet analysis function with manual intervention as necessary. Spectral data are reported as follows: chemical shift (multiplicity [singlet (s), broad singlet (brs), doublet (d), triplet (t), quartet (q), pentet (p), multiplet (m), doublet of doublets (dd), doublet of doublet of doublets (ddd), doublet of triplet of doublets (dtd), doublet of doublet of doublet of doublets (dddd), doublet of triplets (dt), triplet of doublets (td), etc.], coupling constant, integration). Chemical shifts are reported in ppm (δ), and coupling constants are reported in Hz. ¹H Resonances are referenced to solvent residual peaks for CDCl₃ (7.26 ppm), CD₂Cl₂ (5.32 ppm), DMSO-*d*₆ (2.50 ppm), D₂O (4.79 ppm), CD₃CN (1.79 ppm), or CD₃OD (3.31 ppm).¹ Routine ¹³C NMR spectra were recorded on Agilent 400, 500, or 600 MHz spectrometers with protons fully decoupled. ¹³C Resonances are reported in ppm relative to solvent residual peaks for CDCl₃ (77.16 ppm), CD₂Cl₂ (53.84 ppm) or CD₃OD (49.0 ppm).¹ Note: Small deviations in chemical shifts may be observed depending on the concentration of NMR samples.

Infrared spectra were recorded on a Nicolet 6700 ATR/FT-IR spectrometer, and ν_{\max} are partially reported in cm⁻¹. High-resolution mass spectrometry was performed by Chemical and Biophysical Instrumentation Center at Yale University, on a Waters Xevo Q-TOF high-resolution Mass Spectrometry using ESI. Ultra high-performance liquid chromatography-mass spectrometry (UPLC/MS) was performed on a Waters Acquity SQD2 instrument equipped with an Ultra BEH C-18 column (1.7 μm particle size, 2.1 × 50 mm), a dual atmospheric pressure chemical ionization (API)/electrospray ionization S4 (ESI) mass spectrometry detector, and a photodiode array detector. Analytical thinlayer chromatography was performed using 60 Å Silica Gel F254 pre-coated plates (0.25 mm thickness). TLC plates were visualized by irradiation with a UV lamp. *R_f* values are reported. Normal-phase column chromatography was performed using 60 Å Silica Gel (32–62 micron) with an appropriate mobile phase composition and gradient. Optical rotations were recorded on a Perkin-Elmer Polarimeter 341 at the sodium D-line (589 nm) using a cell of 50 mm path length. Measurements were recorded at 20 °C. Concentration

values are reported in units of g/100 mL. Normal-phase high-performance liquid chromatography was performed using an Agilent 1100 series instrument equipped with a diode array detector and columns (chiral supports) from Daicel Chemical Industries.


In many cases, normal-phase flash chromatography was performed using a Biotage Isolera One purification system equipped with a 10, 25, 50 or 100 g SNAP Ultra (HP Sphere, 25 μ m silica) cartridge and an appropriate EtOAc/Hex linear gradient in the mobile phase. Reversed-phase column chromatography was performed using a Biotage Isolera One purification system equipped with a 15, 30, 60 or 120 g SNAP-C18 column and an appropriate MeOH/H₂O or MeCN/H₂O linear gradient in the mobile phase.

1.1 Abbreviation

Aib	2-aminoisobutyric acid
Boc	<i>tert</i> -Butoxycarbonyl
CDCl ₃	Chloroform- <i>d</i>
CD ₂ Cl ₂	Methylene chloride- <i>d</i> ₂
CD ₃ OD	Methanol- <i>d</i> ₄
DCM	Dichloromethane
DIPEA	<i>N,N</i> -Diisopropylethylamine
DMF	<i>N,N</i> -Dimethylformamide
DMSO	Dimethylsulfoxide
EDC	1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
EtOAc	Ethyl acetate
EtOH	Ethanol
HBTU	(2-(1 <i>H</i> -benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
Hex	Hexanes
HOBt	1-Hydroxybenzotriazole
HPLC	High-performance liquid chromatography
HRMS	High-resolution mass spectrometry
IPA	Isopropyl alcohol
LC-MS	Liquid chromatography mass spectrometry
MeCN	Acetonitrile
MeOH	Methanol
NBS	<i>N</i> -Bromosuccinimide
rt	Room temperature
TFA	Trifluoroacetic acid, trifluoroacetate
THF	Tetrahydrofuran
TBS	<i>tert</i> -Butyldimethylsilyl
UPLC	Ultra Performance Liquid Chromatography
TLC	Thin-layer chromatography
TMG	Tetramethylguanidine
Tol	Toluene


2. Synthesis of Guanidinylated Amino Acid Ligands

Guanidinylated ligands used in this study (**L1**, *ent*-**L2**, **L2**, **L3** and *ent*-**L4**) were prepared by following the previously reported procedures.² Example synthesis is shown below:




3. Synthesis of Diarylmethane

Diarylmethane **1** was prepared by following the previously reported procedures.^{2a}



4. Synthesis of Bifunctional Nucleophiles

4.1 General Synthetic Routes for Bifunctional Nucleophiles:



4.2 General Procedure 1: Sonogashira Coupling

To a flame-dried RBF equipped with a magnetic stir bar was added aryl iodide (1.00 equiv), Pd(PPh₃)₂Cl₂ (0.02 equiv) and CuI (0.04 equiv). Reaction vessel was evacuated and backfilled with N₂ × 3. Dry Et₃N (1.0 M) (distilled over CaH₂ and stored under N₂) was added through the septa. To the stirring mixture was added alcohol (1.20 equiv). Reaction mixture was left to stir for 4–15 h until reaction was complete (monitored by TLC). The reaction mixture was diluted with EtOAc and washed with sat. NH₄Cl (aq). Aqueous layer

was extracted with EtOAc \times 3. Combined organic layers were washed with sat. NaCl (aq), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified by flash chromatography to afford the desired material.

4.3 General Procedure 2: Acylation of Alcohols


To a flame-dried RBF equipped with magnetic stir bar was added nitrobenzene **S1–S8** (1.00 equiv) and anhydrous THF (0.12 M). Reaction mixture was cooled to 0 °C. Dry pyridine (1.50 equiv) distilled over CaH₂ was added dropwise to the stirring mixture. Ethyl malonyl chloride (1.20 equiv) in THF (1.00 M) was subsequently added dropwise to the stirring mixture. Reaction mixture was warmed to room temperature, and left to stir for 2 hours until reaction was complete (monitored by TLC). Reaction mixture was diluted with CH₂Cl₂ and quenched with 10% (w/v) citric acid (aq). Aqueous layer was extracted with CH₂Cl₂ \times 3. Combined organic layers were washed with sat. NaCl (aq), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The crude material was then purified by flash chromatography to afford desired material.

4.4 General Procedure 3: Hydrogenolysis & Nitro Reduction

To a flame-dried RBF equipped with magnetic stir bar was added nitrobenzene **S9–S16** and MeOH (0.5 M). Reaction mixture was sparged with N₂ for 15 minutes. Pd/C (10 wt % – 50% wet with water) was added to the reaction mixture then further sparged with N₂ for 15 minutes. Atmosphere was switched to H₂ via balloon and reaction mixture was left to stir overnight (15 h) at room temperature. The mixture was filtered through Celite ® and concentrated *in vacuo*. The crude material was purified by silica chromatography to afford the desired products.

5. Characterization and Spectra of Bifunctional Nucleophiles and Intermediates

5.1 Cross-coupled Products



4-(4-methyl-3-nitrophenyl)but-3-yn-1-ol (S1) was synthesized from 4-iodo-1-methyl-2-nitrobenzene following **General Procedure 1**. Crude material was purified by silica chromatography (0→40→60% EtOAc/Hex) to yield **S1** as an orange solid (1.5392 g, 99% yield).


TLC (40% EtOAc/Hex): R_f = 0.40.

IR (FT-ATR, cm⁻¹, neat): ν_{max} 3245, 2934, 2086, 2078, 1521, 1445, 1377, 1344, 1054, 1025, 857, 667.

¹H NMR (600 MHz, CDCl₃) δ 7.99 (s, 1H), 7.51 – 7.47 (m, 1H), 7.26–25 (m, 1H), 3.83 (t, *J* = 6.2 Hz, 2H), 2.69 (t, *J* = 6.3 Hz, 2H), 2.57 (s, 3H), 1.92 (s, 1H).


¹³C NMR (151 MHz, CDCl₃) δ 149.1, 135.8, 133.3, 132.9, 127.8, 122.7, 88.9, 80.2, 61.1, 23.8, 20.5.

HRMS (ESI/Q-TOF): Exact mass calculated for [C₁₁H₁₁NO₃ + H]⁺ requires *m/z* = 206.0817, found *m/z* = 206.0820.




S2

4-(3-nitrophenyl)but-3-yn-1-ol (S2) was synthesized from 1-iodo-3-nitrobenzene following **General Procedure 1**. Crude material was purified by silica chromatography (0→40% EtOAc/Hex) to yield **S2** as a beige solid (1.6193 g, 92% yield). Characterization data is in agreement with reported values.³



S3

4-(1-methoxy-4-nitronaphthalen-2-yl)but-3-yn-1-ol (S3) was synthesized from 2-iodo-1-methoxy-4-nitronaphthalene⁴ following **General Procedure 1**. Crude material was purified by silica chromatography (0→30→60% EtOAc/Hex) to yield **S3** as a yellow solid (1.3970g, 89% yield). Characterization data is in agreement with reported values.⁴



S4

4-(2-methoxy-5-nitrophenyl)but-3-yn-1-ol (S4) was synthesized from 2-iodo-1-methoxy-4-nitrobenzene following **General Procedure 1**. Crude material was purified by flash chromatography (0→30→ 50% EtOAc/Hex) to yield **S4** as a beige solid (1.0670 g, 93% yield).


TLC (30% EtOAc/Hex): *R_f* = 0.27.

¹H NMR (400 MHz, CD₂Cl₂) δ 8.25 – 8.22 (m, 1H), 8.16 (dd, *J* = 9.2, 2.7 Hz, 1H), 6.95 (d, *J* = 9.2 Hz, 1H), 3.96 (s, 3H), 3.79 (q, *J* = 6.2 Hz, 2H), 2.71 (t, *J* = 6.2 Hz, 2H), 1.93 (t, *J* = 6.3 Hz, 1H).

¹³C NMR (101 MHz, CD₂Cl₂) δ 165.2, 144.4, 129.2, 125.6, 114.0, 110.8, 93.8, 76.8, 61.2, 57.1, 24.4.


IR (FT-ATR, cm^{-1} , neat): ν_{max} 3268, 3078, 2947, 2883, 2338, 1577, 1504, 1332, 1266, 1093, 928.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{11}\text{H}_{11}\text{NO}_4 + \text{H}]^+$ requires $m/z = 222.0761$, found $m/z = 222.0755$.




S5

5-(3-nitrophenyl)pent-4-yn-1-ol (S5) was synthesized from 1-iodo-3-nitrobenzene following **General Procedure 1**. Crude material was purified by silica chromatography (0→30→60% EtOAc/Hex) to yield **S5** as a pale yellow oil (1.7003g, quantitative yield). Characterization data is in agreement with reported values.⁵



S6

3-(3-nitrophenyl)prop-2-yn-1-ol (S6) was synthesized from 1-iodo-3-nitrobenzene following **General Procedure 1**. Crude material was purified by silica chromatography (0→40% EtOAc/Hex) to yield **S6** as a light brown oil (0.4808 g, 92% yield). Characterization data is in agreement with reported values.⁶



S7

4-(2-nitrophenyl)but-3-yn-1-ol (S7) was synthesized from 1-iodo-2-nitrobenzene following **General Procedure 1**. Crude material was purified by silica chromatography (0→50→80% EtOAc/Hex) to yield **S7** as a brown oil (3.7858 g, 98% yield).


TLC (50% EtOAc/Hex): 0.46.

^1H NMR (400 MHz, CDCl_3) δ 8.05–7.96 (m, 1H), 7.68–7.51 (m, 2H), 7.48–7.38 (m, 1H), 3.86 (t, $J = 6.0$ Hz, 2H), 2.75 (t, $J = 6.0$ Hz, 2H), 2.16 (s, 1H).

^{13}C NMR (101 MHz, CDCl_3) δ 150.2, 134.8, 133.0, 128.5, 124.8, 118.9, 95.8, 78.1, 61.0, 24.4.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3373, 2886, 2335, 1519, 1479, 1340, 1039, 743.


HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{10}\text{H}_9\text{NO}_3 + \text{H}]^+$ requires $m/z = 192.0655$, found $m/z = 192.0665$.



S8

5-(2-nitrophenyl)pent-4-yn-1-ol (S8) was synthesized from 1-iodo-2-nitrobenzene following **General Procedure 1**. Crude material was purified by silica chromatography (0→50→80% EtOAc/Hex) to yield **S8** as a brown oil (2.8462 g, 84% yield). Characterization data is in agreement with reported values.⁷

5.2 Acylation Products



S9

Ethyl (4-(4-methyl-3-nitrophenyl)but-3-yn-1-yl) malonate (S9) was synthesized from **S1** following **General Procedure 2**. Crude material was purified by silica chromatography (0→20→50% EtOAc/Hex) to yield **S9** as a pale yellow oil (1.2873 g, 69% yield).


TLC (30% EtOAc/Hex): $R_f = 0.48$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 2991, 2119, 1731, 1527, 1332, 1145, 1030, 832.

^1H NMR (600 MHz, CDCl_3) δ 7.99 (d, $J = 1.3$ Hz, 1H), 7.50 (dd, $J = 7.9, 1.4$ Hz, 1H), 7.27 (d, $J = 7.4$ Hz, 1H), 4.34 (t, $J = 6.8$ Hz, 2H), 4.21 (q, $J = 7.1$ Hz, 2H), 3.42 (s, 2H), 2.79 (t, $J = 6.8$ Hz, 2H), 2.58 (s, 3H), 1.27 (t, $J = 7.1$ Hz, 2H).

^{13}C NMR (151 MHz, CDCl_3) δ 166.5, 166.5, 149.2, 135.8, 133.4, 132.9, 127.8, 122.6, 87.4, 80.0, 63.1, 61.8, 41.6, 20.5, 19.9, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{16}\text{H}_{17}\text{NO}_6 + \text{H}]^+$ requires $m/z = 320.1129$, found $m/z = 320.1143$.



S10

Ethyl (4-(3-nitrophenyl)but-3-yn-1-yl) malonate (S10) was synthesized from **S2** following **General Procedure 2**. Crude material was purified by silica chromatography (0→30→50% EtOAc/Hex) to yield **S10** as a pale yellow oil (1.9685 g, 76% yield).


TLC (20% EtOAc/Hex): $R_f = 0.38$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3084, 2961, 2114, 1730, 1528, 1369, 1350, 1144, 1030, 899.

^1H NMR (500 MHz, CDCl_3): δ 8.24 (s, 1H), 8.13 (d, $J = 8.2$ Hz, 1H), 7.69 (d, $J = 7.7$ Hz, 1H), 7.47 (t, $J = 8.0$ Hz, 1H), 4.35 (t, $J = 6.7$ Hz, 2H), 4.20 (q, $J = 7.1$ Hz, 2H), 3.42 (s, 2H), 2.80 (t, $J = 6.7$ Hz, 2H), 1.27 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 166.5, 166.4, 148.2, 137.5, 129.4, 126.6, 125.2, 122.9, 88.3, 80.1, 63.0, 61.8, 41.6, 19.9, 14.2.

HRMS(ESI/Q-TOF): Exact mass calculated for $[\text{C}_{15}\text{H}_{15}\text{NO}_6 + \text{H}]^+$ requires $m/z = 306.0972$, found $m/z = 306.0970$.



S11


Ethyl (4-(1-methoxy-4-nitronaphthalen-2-yl)but-3-yn-1-yl) malonate (S11) was synthesized from **S3** following **General Procedure 2**. Crude material was purified by silica chromatography (0 \rightarrow 25% EtOAc/Hex) to yield **S11** as a yellow oil (0.8845 g, 87% yield). TLC (30% EtOAc/Hex): $R_f = 0.35$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 2965, 2906, 2084, 1751, 1720, 1620, 1511, 1321, 1269, 1143, 1037, 785.

^1H NMR (400 MHz, CDCl_3): δ 8.62 (d, $J = 8.7$ Hz, 1H), 8.30 (dd, $J = 9.0, 1.5$ Hz, 2H), 7.73 (ddd, $J = 8.7, 6.9, 1.4$ Hz, 1H), 7.62 (ddd, $J = 8.3, 6.9, 1.2$ Hz, 1H), 4.40 (t, $J = 6.7$ Hz, 2H), 4.29 (s, 3H), 4.21 (q, $J = 7.1$ Hz, 2H), 3.43 (s, 2H), 2.90 (t, $J = 6.7$ Hz, 2H), 1.28 (t, $J = 7.2$ Hz, 3H).

^{13}C NMR (151 MHz, CDCl_3) δ 166.5, 166.4, 162.5, 141.3, 130.4, 130.2, 128.6, 127.7, 126.3, 123.6, 123.4, 108.5, 92.5, 77.6, 63.1, 61.9, 61.8, 41.6, 20.3, 14.2.

HRMS(ESI/Q-TOF): Exact mass calculated for $[\text{C}_{20}\text{H}_{19}\text{NO}_7 + \text{H}]^+$ requires $m/z = 386.1234$, found $m/z = 386.1231$.



S12

Ethyl (4-(2-methoxy-5-nitrophenyl)but-3-yn-1-yl) malonate (S12) was synthesized from **S4** following **General Procedure 2**. Crude material was purified by silica chromatography (10 \rightarrow 50% EtOAc/Hex) to yield the desired product **S12** as a yellow oil (1.5077 g, quantitative yield).


TLC (50% EtOAc/Hex): $R_f = 0.50$

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3080, 2970, 1729, 1514, 1340, 1230, 1013, 749.

^1H NMR (600 MHz, CDCl_3): δ 8.27 (d, $J = 2.8$ Hz, 1H), 8.18 (dd, $J = 9.2, 2.8$ Hz, 1H), 6.92 (d, $J = 9.2$ Hz, 1H), 4.36 (t, $J = 6.9$ Hz, 2H), 4.21 (q, $J = 7.1$ Hz, 2H), 3.98 (s, 3H), 3.42 (s, 2H), 2.85 (t, $J = 6.9$ Hz, 2H), 1.28 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (151 MHz, CDCl_3): δ 166.6, 166.5, 164.7, 141.2, 129.4, 125.5, 113.7, 110.3, 91.8, 76.4, 63.1, 61.8, 56.7, 41.6, 20.2, 14.2.

HRMS(ESI/Q-TOF): Exact mass calculated for $[\text{C}_{16}\text{H}_{17}\text{NO}_7 + \text{Na}]^+$ requires $m/z = 358.0897$, found $m/z = 358.0926$.



S13

Ethyl (5-(3-nitrophenyl)pent-4-yn-1-yl) malonate (S13) was synthesized from **S5** following **General Procedure 2**. Crude material was purified by silica chromatography (0→30→50% EtOAc/Hex) to provide the desired product as a yellow oil (2.1051 g, 89% yield).


TLC (40% EtOAc/Hex): $R_f = 0.50$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 2961, 2324, 1729, 1528, 1368, 1349, 1146, 1031, 761, 674.

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.22 (s, 1H), 8.17 – 8.08 (m, 1H), 7.68 (d, $J = 7.7$ Hz, 1H), 7.46 (t, $J = 8.0$ Hz, 1H), 4.32 (t, $J = 6.2$ Hz, 2H), 4.21 (q, $J = 7.1$ Hz, 2H), 3.40 (s, 2H), 2.55 (t, $J = 7.0$ Hz, 2H), 1.98 (p, $J = 6.7$ Hz, 2H), 1.29 (t, $J = 7.1$ Hz, 3H).

$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 166.7, 166.6, 148.2, 137.5, 129.4, 126.6, 125.6, 122.7, 91.6, 79.4, 64.1, 61.8, 48.4, 41.7, 27.6, 16.2, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{16}\text{H}_{17}\text{NO}_6 + \text{H}]^+$ requires $m/z = 320.1129$, found $m/z = 320.1132$.



S14

Ethyl (3-(3-nitrophenyl)prop-2-yn-1-yl) malonate (S14) was synthesized from **S6** following **General Procedure 2**. The crude material was then purified by silica chromatography (0→30→50% EtOAc/Hex) followed by reversed-phase chromatography (0→95% MeCN/ H_2O) to provide the desired product as a clear oil (0.5711 g, 72% yield).


TLC (40% EtOAc/Hex): $R_f = 0.64$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3084, 2964, 2324, 1754, 1731, 1529, 1370, 1350, 1140, 1029, 762, 735.

$^1\text{H NMR}$ (600 MHz, CDCl_3): δ 8.32 – 8.29 (m, 1H), 8.20 (ddd, $J = 8.3, 2.2, 0.9$ Hz, 1H), 7.75 (d, $J = 7.7$ Hz, 1H), 7.52 (t, $J = 8.0$ Hz, 1H), 4.99 (s, 2H), 4.23 (q, $J = 7.1$ Hz, 2H), 3.47 (s, 2H), 1.29 (t, $J = 7.1$ Hz, 3H).

$^{13}\text{C NMR}$ (151 MHz, CDCl_3): δ 166.2, 166.0, 148.2, 137.6, 129.6, 126.9, 124.0, 123.8, 85.1, 84.5, 61.9, 53.4, 41.4, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{14}\text{H}_{13}\text{NO}_6 + \text{H}]^+$ requires $m/z = 292.0816$, found $m/z = 292.0844$.



S15

Ethyl (4-(2-nitrophenyl)but-3-yn-1-yl) malonate (S15) was synthesized from **S7** following **General Procedure 2**. Crude material was purified by silica chromatography (0→25→40% EtOAc/Hex) to provide the desired product as a yellow oil (453.3 g, quantitative yield).


TLC (30% EtOAc/Hex): $R_f = 0.54$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 2982, 2119, 1730, 1609, 1524, 1369, 1340, 1144, 1030, 745.

^1H NMR (400 MHz, CDCl_3) δ 7.99 (d, $J = 8.2$ Hz, 1H), 7.56 (dt, $J = 15.0, 7.7$ Hz, 2H), 7.43 (t, $J = 7.7$ Hz, 1H), 4.37 (t, $J = 6.7$ Hz, 2H), 4.20 (q, $J = 7.1$ Hz, 2H), 3.44 (s, 2H), 2.85 (t, $J = 6.7$ Hz, 2H), 1.26 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.6, 166.5, 150.3, 135.0, 132.8, 128.6, 124.6, 118.7, 93.9, 77.6, 62.9, 61.7, 41.6, 20.3, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{15}\text{H}_{17}\text{NO}_6 + \text{H}]^+$ requires $m/z = 306.0972$, found $m/z = 306.0976$.



S16

Ethyl (5-(2-nitrophenyl)pent-4-yn-1-yl) malonate (S16) was synthesized from **S8** following **General Procedure 2**. Crude material was purified by silica chromatography (0→30→60% EtOAc/Hex) to provide the desired product as a yellow oil (0.3277 g, 92% yield).

TLC (30% EtOAc/Hex): $R_f = 0.48$.


IR (FT-ATR, cm^{-1} , neat): ν_{max} 2981, 2230, 1728, 1524, 1368, 1341, 1186, 1145, 1030, 745.

^1H NMR (400 MHz, CDCl_3) δ 7.98 (d, $J = 8.3$ Hz, 1H), 7.54 (dt, $J = 15.0, 7.7$ Hz, 2H), 7.41 (t, $J = 7.7$ Hz, 1H), 4.34 (t, $J = 6.2$ Hz, 2H), 4.21 (q, $J = 7.1$ Hz, 2H), 3.39 (s, 2H), 2.59 (t, $J = 7.0$ Hz, 2H), 2.00 (p, $J = 6.6$ Hz, 2H), 1.28 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.7, 166.7, 150.2, 134.9, 132.8, 128.3, 124.6, 119.0, 97.3, 76.9, 64.1, 61.7, 41.7, 27.5, 16.6, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{16}\text{H}_{17}\text{NO}_6 + \text{H}]^+$ requires $m/z = 342.0952$, found $m/z = 342.0948$.

5.3 Hydrogenolysis Products: Bifunctional Nucleophiles



2a

4-(3-amino-4-methylphenyl)butyl ethyl malonate (2a) was synthesized from **S9** following **General Procedure 3**. The crude material was purified by flash chromatography (0→40% EtOAc/Hex) to yield the desired product as a pale yellow oil (1.1674 g, 98% yield).


TLC (40% EtOAc/Hex): 0.50.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3466, 3378, 2937, 2660, 2101, 1727, 1627, 1329, 1270, 1146, 1030, 734.

^1H NMR (500 MHz, CDCl_3) δ 6.95 (d, $J = 7.5$ Hz, 1H), 6.65 – 6.39 (m, 2H), 4.29 – 3.92 (m, 4H), 3.56 (s, 2H), 3.36 (s, 2H), 2.53 (t, $J = 7.0$ Hz, 2H), 2.13 (s, 3H), 1.81 – 1.56 (m, 4H), 1.27 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 166.8, 166.7, 144.6, 140.9, 130.5, 120.0, 118.8, 115.1, 65.6, 61.7, 41.8, 35.1, 28.2, 27.6, 17.1, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{16}\text{H}_{23}\text{NO}_4 + \text{H}]^+$ requires $m/z = 294.1700$, found $m/z = 294.1697$.



4-(3-aminophenyl)butyl ethyl malonate (2b) was synthesized from **S10** following **General Procedure 3**. The crude material was purified by flash chromatography (0→30→50% EtOAc/Hex) to provide the desired product as a pale yellow oil (2.2495 g, 90% yield).


TLC (40% EtOAc/Hex): $R_f = 0.50$.

IR (FT-ATR, cm^{-1} , neat): 3467, 3376, 2941, 2860, 1725, 1622, 1331, 1268, 1148, 1030, 866., 734.

^1H NMR (600 MHz, CDCl_3): δ 7.06 (t, $J = 7.6$ Hz, 1H), 6.58 (d, $J = 7.5$ Hz, 1H), 6.53 (d, $J = 7.6$ Hz, 2H), 4.27 – 3.96 (m, 4H), 3.69 (s, 1H), 3.36 (s, 2H), 2.55 (t, $J = 7.0$ Hz, 2H), 1.67 (dd, $J = 6.6, 3.1$ Hz, 6H), 1.27 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (151 MHz, CDCl_3): δ 166.8, 166.7, 146.4, 143.3, 129.4, 119.0, 115.4, 113.0, 65.6, 61.7, 41.8, 35.5, 28.2, 27.5, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{15}\text{H}_{21}\text{NO}_4 + \text{H}]^+$ requires $m/z = 280.1549$, found $m/z = 280.1561$.



4-(4-amino-1-methoxynaphthalen-2-yl)butyl ethyl malonate (2c) was synthesized from **S11** following **General Procedure 3**. The crude material was purified by flash chromatography (0→50→70% EtOAc/Hex) to yield **2c** as a purple oil (1.6614 g, quantitative yield).


TLC (50% EtOAc/Hex): $R_f = 0.57$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3444, 3367, 2936, 2864, 2108, 1981, 1725, 1628, 1464, 1382, 1370, 1228, 1148, 1030, 764, 708.

^1H NMR (600 MHz, CDCl_3) δ 8.05 (d, $J = 8.4$ Hz, 1H), 7.81 (d, $J = 8.4$ Hz, 1H), 7.50 (t, $J = 7.6$ Hz, 1H), 7.44 (t, $J = 7.6$ Hz, 1H), 6.66 (s, 1H), 4.24 – 4.13 (m, 4H), 3.85 (s, 3H), 3.36 (s, 2H), 2.78 – 2.73 (m, 2H), 1.74 (p, $J = 3.5$ Hz, 4H), 1.25 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (151 MHz, CDCl_3): δ 166.8, 166.7, 146.8, 137.7, 130.4, 128.7, 126.1, 124.8, 124.0, 122.7, 121.4, 112.0, 77.2, 65.5, 62.2, 61.7, 41.8, 29.2, 28.4, 27.0, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{20}\text{H}_{25}\text{NO}_5 + \text{H}]^+$ requires $m/z = 360.1806$, found $m/z = 360.1810$.



2d

4-(5-amino-2-methoxyphenyl)butyl ethyl malonate (2d) was synthesized from **S12** following **General Procedure 3**. The crude material was purified by flash chromatography (0 \rightarrow 45 \rightarrow 70 % EtOAc/Hex) to yield **2d** as a red-brown oil (1.2556 g, 93% yield).


TLC (40% EtOAc/Hex): $R_f = 0.41$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3442, 3365, 2943, 2832, 2114, 1726, 1501, 1369, 1229, 1146, 1029, 855.

^1H NMR (600 MHz, CDCl_3): δ 6.69 – 6.65 (m, 1H), 6.51 (d, $J = 6.4$ Hz, 2H), 4.19 (dt, $J = 20.8, 6.9$ Hz, 4H), 3.74 (s, 3H), 3.43 – 3.34 (m, 4H), 2.56 (t, $J = 7.4$ Hz, 2H), 1.66 (dp, $J = 31.5, 8.4, 7.7$ Hz, 4H), 1.27 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3): 166.9, 166.8, 151.0, 139.8, 131.5, 117.8, 113.6, 111.9, 65.7, 61.7, 56.1, 41.9, 29.7, 28.3, 26.2, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{16}\text{H}_{23}\text{NO}_5 + \text{H}]^+$ requires $m/z = 310.1649$, found $m/z = 310.1678$.



2e

5-(3-aminophenyl)pentyl ethyl malonate (2e) was synthesized from **S13** following **General Procedure 3**. The crude material was purified by silica chromatography (0 \rightarrow 40% EtOAc/Hex) to yield **2e** as an orange-yellow oil (1.6596 g, 94% yield).


TLC (40% EtOAc/Hex): $R_f = 0.50$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3467, 3376, 2936, 2857, 1723, 1622, 1330, 1272, 1148, 1031, 955.

^1H NMR (600 MHz, CDCl_3) δ 7.07 (t, $J = 7.9$ Hz, 1H), 6.59 (d, $J = 7.5$ Hz, 1H), 6.54 (d, $J = 7.0$ Hz, 2H), 4.20 (q, $J = 7.1$ Hz, 2H), 4.14 (t, $J = 6.7$ Hz, 2H), 3.72 (brs, 2H), 3.36 (s, 2H), 2.60 – 2.45 (m, 2H), 1.76 – 1.56 (m, 4H), 1.46 – 1.34 (m, 2H), 1.28 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (151 MHz, CDCl_3) δ 166.8, 166.7, 146.1, 143.8, 129.3, 119.2, 115.6, 113.0, 65.7, 61.6, 41.8, 35.9, 30.9, 28.5, 25.6, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{20}\text{H}_{25}\text{NO}_5 + \text{H}]^+$ requires $m/z = 294.1700$, found $m/z = 294.1689$.



S17

3-(3-aminophenyl)propyl ethyl malonate (S17) was synthesized from **S14** following **General Procedure 3**. The crude material was purified by flash chromatography (0 \rightarrow 20 \rightarrow 40% EtOAc/Hex) to yield the **S17** as an orange oil (0.1053 g, 38% yield).


TLC (40% EtOAc/Hex): $R_f = 0.38$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3467, 3376, 2981, 2348, 1724, 1623, 1604, 1330, 1271, 1148, 1028, 911.

^1H NMR (400 MHz, CDCl_3) δ 7.07 (t, $J = 7.7$ Hz, 1H), 6.58 (d, $J = 7.4$ Hz, 1H), 6.53 (d, $J = 7.6$ Hz, 2H), 4.21 (q, $J = 7.1$ Hz, 2H), 4.16 (t, $J = 6.5$ Hz, 2H), 3.87 (brs, 2H), 3.38 (s, 2H), 2.66–2.38 (m, 2H), 2.05–1.86 (m, 2H), 1.29 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.8, 166.7, 146.5, 142.4, 129.5, 118.9, 115.4, 113.1, 65.0, 61.7, 41.8, 32.1, 30.0, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{14}\text{H}_{19}\text{NO}_4 + \text{H}]^+$ requires $m/z = 266.1388$, found $m/z = 266.1387$.



S18

4-(2-aminophenyl)butyl ethyl malonate (S18) was synthesized from **S15** following **General Procedure 3**. The crude material was purified by flash chromatography (0 \rightarrow 40 \rightarrow 75% EtOAc/Hex) to yield **S4** as a pale yellow oil (0.1119 g, 89% yield).


TLC (40% EtOAc/Hex): $R_f = 0.59$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3470, 3378, 2940, 2865, 2101, 1725, 1625, 1497, 1330, 1271, 1147, 1030, 749.

^1H NMR (400 MHz, CDCl_3) δ 7.08 – 6.99 (m, 2H), 6.73 (t, $J = 7.4$ Hz, 1H), 6.68 (d, $J = 7.8$ Hz, 1H), 4.26 – 4.07 (m, 4H), 3.37 (s, 2H), 2.53 (t, $J = 7.3$ Hz, 2H), 1.90 – 1.62 (m, 6H), 1.27 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 166.9, 166.7, 144.2, 129.6, 127.2, 126.1, 118.9, 115.8, 77.2, 65.4, 61.7, 41.8, 30.9, 28.5, 25.0, 14.2.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{15}\text{H}_{21}\text{NO}_4 + \text{H}]^+$ requires $m/z = 280.1542$, found $m/z = 280.1543$.



S19

5-(2-aminophenyl)pentyl ethyl malonate (S19) was synthesized from **S16** following **General Procedure 3**. The crude material was purified by flash chromatography (0→35→70% EtOAc/Hex) to yield **S19** as an orange oil (0.2561 g, 82% yield).



TLC (40% EtOAc/Hex): R_f = 0.61.



IR (FT-ATR, cm^{-1} , neat): ν_{max} 3466, 3380, 2935, 2860, 2113, 1725, 1624, 1497, 1330, 1269, 1147, 1031, 749.


$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.02 (d, J = 7.4 Hz, 2H), 6.77 – 6.61 (m, 2H), 4.31 – 4.06 (m, 4H), 3.69 (d, J = 10.3 Hz, 1H), 3.37 (s, 2H), 2.71 – 2.43 (m, 2H), 1.86 – 1.61 (m, 6H), 1.45 (p, J = 7.5 Hz, 3H), 1.28 (t, J = 7.1 Hz, 3H).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 166.8, 166.7, 144.1, 129.6, 127.1, 126.6, 119.0, 115.8, 65.6, 61.7, 41.8, 31.3, 28.5, 28.4, 25.9, 14.2.



HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{16}\text{H}_{23}\text{NO}_4 + \text{H}]^+$ requires m/z = 294.1696, found m/z = 294.1700.









S7
(¹H NMR, CDCl₃, 400 MHz)





S7
(¹³C NMR, CDCl₃, 101 MHz)










S9
(^1H NMR, CDCl_3 , 600 MHz)







S9
(^{13}C NMR, CDCl_3 , 151 MHz)






















S15
(¹H NMR, CDCl₃, 400 MHz)





S15
(¹³C NMR, CDCl₃, 101 MHz)









S16
(¹H NMR, CDCl₃, 400 MHz)





S16
(¹³C NMR, CDCl₃, 101 MHz)












2b
(¹H NMR, CDCl₃, 600 MHz)




2b
(¹³C NMR, CDCl₃, 151 MHz)













2e
(¹H NMR, CDCl₃, 600 MHz)






2e
(¹³C NMR, CDCl₃, 151 MHz)







S17
(¹H NMR, CDCl₃, 400 MHz)







S19
(¹H NMR, CDCl₃, 400 MHz)





S18
(¹³C NMR, CDCl₃, 101 MHz)






S19
(¹H NMR, CDCl₃, 400 MHz)




S19
(¹³C NMR, CDCl₃, 126 MHz)




6. Synthesis of Aminophenol 2f

6.1 General Synthetic Route to 2f



6.2 Characterization of Aminophenol 2f and Intermediates (3-bromo-5-nitrophenoxy)(*tert*-butyl)dimethylsilane (S20)



To a RBF equipped with a magnetic stir bar was added 3-bromo-5-nitrophenol (2.000 g, 9.17 mmol, 1.00 equiv), TBSCl (1.5210 g, 10.09 mmol, 1.10 equiv) and CH₂Cl₂ (9.17 mL, 1.0 M). Reaction mixture was cooled to 0 °C. Imidazole (0.6243 g, 9.17 mmol, 1.00 equiv) was added in one portion to the stirring mixture. Reaction mixture was allowed to warm to room temperature and was left to stir for 3 hours (until consumption of the starting material was observed by TLC). Reaction mixture was diluted with CH₂Cl₂ (10 mL) and washed with 10% citric acid (w/v) (20 mL). Aqueous layer was extracted with CH₂Cl₂ (10 mL × 3). Combined organic layers were washed with saturated NaCl (aq) (40 mL), dried over Na₂SO₄, filtered and concentrated in vacuo to yield an orange-brown solid. Crude material was used without in the subsequent step without further purification (2.8996 g, 95% yield). **TLC** (1% EtOAc/Hex): R_f = 0.35.


IR (FT-ATR, cm⁻¹, neat): ν_{max} 3090, 2954, 2930, 2859, 1980, 1532, 1450, 1343, 1274, 1096, 999, 839, 664.

¹H NMR (500 MHz, CDCl₃) δ 7.98 (t, *J* = 1.8 Hz, 1H), 7.59 (t, *J* = 2.1 Hz, 1H), 7.30 (t, *J* = 1.9 Hz, 1H), 1.00 (s, 9H), 0.26 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 157.2, 149.5, 129.6, 122.9, 119.8, 114.1, 25.6, 18.3, -4.4.

HRMS (ESI/Q-TOF): Exact mass calculated for [C₁₂H₁₈BrNO₃Si + H]⁺ requires *m/z* = 332.0312, found *m/z* = 332.0314.

4-(3-((*tert*-butyldimethylsilyl)oxy)-5-nitrophenyl)but-3-yn-1-ol (S21)



To a flame-dried RBF equipped with a magnetic stir bar was added **S20** (2.1667 g, 6.52 mmol, 1.00 equiv), Pd(PPh₃)₂Cl₂ (0.2288 g, 0.33 mmol, 0.05 equiv) and CuI (0.1242 g, 0.65 mmol, 0.10 equiv). RBF was sparged with N₂ for 15 minutes. Dry Et₃N (6.5 mL, 1.0 M) (stored under CaH₂) was added. 3-butyn-1-ol (0.74 mL, 9.78 mmol, 1.50 equiv) (stored under N₂ in a one-dram vial with a septa cap) was added dropwise through the septum. Reaction mixture was left to stir for 3 hours at 60 °C. (Note: Prolonged reaction time leads to decreased yield due to cleavage of the TBS group) Reaction mixture was cooled to room temperature, then diluted with EtOAc (15 mL). Reaction mixture was washed with sat. NH₄Cl (aq) (15 mL). Aqueous layer was extracted with EtOAc (10 mL × 3). Combined organic layers were washed with sat. NaCl(aq) (40 mL), dried over Na₂SO₄, filtered and concentrated in vacuo to yield a viscous brown oil. Crude material was purified by flash chromatography (0→30→60% EtOAc/Hex) to yield **S21** as an orange-brown solid (1.7362 g, 83% yield).


TLC (40% EtOAc/Hex): R_f = 0.54.

IR (FT-ATR, cm⁻¹, neat): ν_{max} 3301, 2935, 2862, 2114, 1530, 1426, 1343, 1256, 1185, 1034, 781.

¹H NMR (400 MHz, CDCl₃) δ 7.89 – 7.82 (m, 1H), 7.58 (t, *J* = 2.2 Hz, 1H), 7.16 (dd, *J* = 2.2, 1.4 Hz, 1H), 3.85 (t, *J* = 6.3 Hz, 2H), 2.71 (t, *J* = 6.3 Hz, 2H), 1.76 (brs, 1H), 0.99 (s, 9H), 0.24 (s, 6H).

¹³C NMR (101 MHz, CDCl₃) δ 156.3, 149.1, 129.2, 125.8, 119.8, 114.9, 89.4, 80.3, 61.1, 25.6, 23.9, 18.3, -4.33.

HRMS (ESI/Q-TOF): Exact mass calculated for [C₁₆H₂₃NO₄Si + H]⁺ requires *m/z* = 322.1469, found *m/z* = 322.1479.



4-(3-((*tert*-butyldimethylsilyl)oxy)-5-nitrophenyl)but-3-yn-1-yl ethyl malonate (S22) was synthesized following from **S21** following **General Procedure 2**. Crude material was purified by flash chromatography (0→20→40% EtOAc/Hex) to yield **S22** as a pale yellow oil (2.2784 g, 97% yield).


TLC (20% EtOAc/Hex): R_f = 0.38.

IR (FT-ATR, cm⁻¹, neat): ν_{max} 2955, 2931, 2859, 2113, 1734, 1614, 1535, 1348, 1256, 1184, 1146, 1032, 840.

¹H NMR (600 MHz, CDCl₃) δ 7.87 – 7.83 (m, 1H), 7.58 (t, *J* = 2.2 Hz, 1H), 7.15 (dd, *J* = 2.2, 1.4 Hz, 1H), 4.34 (t, *J* = 6.8 Hz, 2H), 4.21 (q, *J* = 7.1 Hz, 2H), 3.42 (s, 2H), 2.79 (t, *J* = 6.8 Hz, 2H), 1.27 (t, *J* = 7.1 Hz, 3H), 0.99 (s, 9H), 0.25 (s, 6H).

¹³C NMR (151 MHz, CDCl₃) δ 166.6, 166.5, 156.4, 149.1, 129.2, 125.6, 119.8, 115.0, 87.9, 80.2, 63.0, 61.8, 41.6, 25.7, 19.9, 18.3, 14.2, –4.3.

HRMS (ESI/Q-TOF): Exact mass calculated for [C₂₁H₂₉NO₇Si+H]⁺ requires *m/z* = 436.1786, found *m/z* = 436.1786.



2f

4-(3-amino-5-((*tert*-butyldimethylsilyl)oxy)phenyl)butyl ethyl malonate (2f) was synthesized from **S22** following **General Procedure 3**. Crude material was purified by silica chromatography (0→25→35% EtOAc/Hex) to yield **2f** as an orange oil (2.0160 g, 94% yield).


TLC (30% EtOAc/Hex): *R_f* = 0.50.

IR (FT-ATR, cm⁻¹, neat): *v*_{max} 3468, 3380, 2930, 2957, 1730, 1591, 1330, 1176, 1150, 835.



¹H NMR (600 MHz, CDCl₃) δ 6.13 (s, 1H), 6.08 (s, 1H), 6.03 (t, *J* = 2.0 Hz, 1H), 4.20 (q, *J* = 7.1 Hz, 2H), 4.15 (t, *J* = 6.2 Hz, 2H), 3.58 (s, 2H), 3.36 (s, 2H), 2.47 (t, *J* = 7.1 Hz, 2H), 1.65 (tdt, *J* = 10.7, 7.8, 3.2 Hz, 6H), 1.27 (t, *J* = 7.1 Hz, 2H), 0.97 (s, 9H), 0.18 (s, 6H).

¹³C NMR (151 MHz, CDCl₃) δ 166.8, 166.7, 156.75, 147.5, 144.3, 110.9, 108.8, 104.9, 65.6, 61.7, 60.5, 41.8, 35.4, 28.1, 27.4, 25.8, 21.2, 18.3, 14.2, –4.2.


HRMS (ESI/Q-TOF): Exact mass calculated for [C₂₁H₃₅NO₅Si+H]⁺ requires *m/z* = 410.2357, found *m/z* = 410.2357.




S20
(¹H NMR, CDCl₃, 500 MHz)





S20
(¹³C NMR, CDCl₃, 126 MHz)







S21
(¹H NMR, CDCl₃, 400 MHz)





S21
(¹³C NMR, CDCl₃, 101 MHz)







S22
(¹H NMR, CDCl₃, 600 MHz)





S22
(¹³C NMR, CDCl₃, 151 MHz)







2f
(¹H NMR, CDCl₃, 600 MHz)



2f
(¹³C NMR, CDCl₃, 151 MHz)









7. Bimolecular Competition Experiments: Determination of Chemoselectivity



To an oven-dried 5-mL Schlenk flask was added Cs₂CO₃ (0.2085g, 0.64 mmol, 3.20 equiv). The flask was sealed with a rubber septum and flamed-dried under vacuum. Upon cooling to room temperature, **1** (0.1208 g, 0.2 mmol, 1.00 equiv), Cu(MeCN)₄BF₄ (0.0031 g, 0.01 mmol, 0.05 equiv), **L3** (0.0035g, 0.02 mmol, 0.10 equiv) and a magnetic stir bar were added to the flask. The flask was sealed with a new rubber septum and further secured with Parafilm®. The flask was connected to vacuum for 5 min and backfilled with N₂. This process was repeated two additional times. 1:2 DMF/Tol mixture (0.6 mL) was added through the septum, and the mixture was allowed to stir for 15 min at room temperature, after which nucleophiles were added (0.2 mL of a 1.0 M stock solution w.r.t each nucleophile). The solution was left to stir for 15 h at room temperature. The mixture was diluted with EtOAc and transferred to a separatory funnel. The organic layer washed with a solution of saturated NH₄Cl (aq). The organic layer was separated and the aqueous layer was extracted with EtOAc (5 mL × 3). The organic layer was washed with sat. NaCl (aq) (20 mL). The combined organic layer was then dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. Yield was determined using ¹H NMR by comparing the relative integration of each substrate's methine peak to an internal standard of 1,4-bis(trimethylsilyl)benzene. (Note: In competition experiments between diethyl malonate and aniline, glacial acetic acid was added to convert all C–N coupled products to cyclodehydrated products following previously reported methods.^{2c)})


7.1 Table S1. Bimolecular competition experiments^a

Entry	Nuc	Temp (°C)	SM (%)	Mono C–C (%)	Mono C–N (%)	C–C:C–X ratio
1		23	47	35	5	7.0:1
2		45	37	34	5	7.0:1
3		23	64	31	-	1.:0
4		45	63	34	-	1.:0
5		23	43	28	17	1.6:1
6		45	43	18	30	1:1.7

[a] Conversion determined using ¹H NMR by comparing the relative integration of each substrate's methine peak to an internal standard of 1,4-bis(trimethylsilyl)benzene.


8. Procedures for Cu-catalyzed Intermolecular C–C Coupling

8.1 Procedure 4: Cu-catalyzed Intramolecular C–C Coupling with an Achiral Ligand




Cs_2CO_3 (4.20 equiv) was flamed-dried under vacuum in a 5-mL Schlenk flask. Upon cooling to room temperature, **1** (0.1208 g, 0.2 mmol, 1.00 equiv), $\text{Cu}(\text{MeCN})_4\text{BF}_4$ (0.0031 g, 0.01 mmol, 0.05 equiv), **L3** (0.0035g, 0.02 mmol, 0.10 equiv) and a magnetic stir bar were added to the flask. The flask was sealed with a new rubber septum and further secured with Parafilm M®. The flask was put under vacuum for 5 min and backfilled with N_2 . This process was repeated two additional times. 1:2 DMF/Tol mixture (0.6 mL) was added through the septum, and the mixture was allowed to stir for 15 min at room temperature, after which the bis-nucleophile (1.0 equiv) in 1:2 DMF/Tol mixture (0.2 mL) was added. The solution was left to stir for 15 h at room temperature. The mixture was diluted with EtOAc and transferred to a separatory funnel. The organic layer washed with saturated NH_4Cl (aq). The organic layer was separated and the aqueous layer was extracted with EtOAc (5 mL \times 3). Combined organic layers were washed with sat. NaCl (aq), dried over Na_2SO_4 , filtered, and concentrated in vacuo. The crude material was purified by flash chromatography with EtOAc/Hex gradient.

8.2 Procedure 5: Preparation of Enantioenriched Diarylmethanes by C–C Coupling



Cs_2CO_3 (2.4632 g, 7.56 mmol, 4.20 equiv) was flamed-dried under vacuum in a 10-mL Schlenk flask. Upon cooling to room temperature, **1** (1.0875 g, 1.8 mmol, 1.00 equiv), $\text{Cu}(\text{MeCN})_4\text{BF}_4$ (0.0283 g, 0.09 mmol, 0.05 equiv), **L1** (0.0755 g, 0.18 mmol, 0.10 equiv) and a magnetic stir bar were added to the flask. The flask was sealed with a new rubber septum and further secured with Parafilm M®. The flask was put under vacuum for 5 min and backfilled with N_2 . This process was repeated two additional times. 1:2 DMF/Tol mixture (6.0 mL) was added through the septum, and the mixture was allowed to stir for 15 min at room temperature, after which the bis-nucleophile **2a-2f** (1.98 mmol, 1.10 equiv) in Tol (0.8 mL) was added. The vial was rinsed with DMF (0.4 mL) and added to the stirring mixture. The reaction mixture was left to stir for 15 h at room temperature. The mixture was diluted with EtOAc (20 mL) and transferred to a separatory funnel. The organic layer washed with saturated NH_4Cl (aq) (20 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (10 mL \times 3). Combined organic layers were washed with sat. NaCl (aq) (50 mL), dried over Na_2SO_4 , filtered, and concentrated in vacuo. The crude material was purified by flash chromatography with EtOAc/Hex gradient.


8.3 Procedure 6: TBS Deprotection en route to Aminophenol **3f**



Crude material containing **S23** (~1.8 mmol, 1.00 equiv) was dissolved in THF (9.0 mL, 0.2 M). The solution was cooled to 0 °C. $n\text{-Bu}_4\text{NF}$ (1.0 M solution in THF, 1.98 mmol, 1.10 equiv, 1.98 mL) was added dropwise to the stirring mixture. Reaction mixture was left to stir at 0 °C for 1 h, until the consumption of starting material was observed by TLC. Reaction mixture was diluted with EtOAc and transferred to a separatory funnel. The

organic layer was washed with 10% citric acid (aq). The aqueous layer was extracted with EtOAc \times 3. Combined organic layers were washed with sat. NaCl (aq), dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified by flash chromatography with EtOAc/Hex gradient.

8.4 Characterization and Spectra of Linear Precursors



1-(4-(3-amino-4-methylphenyl)butyl) 3-ethyl 2-(5-((R)-1-(3-bromo-4-(2,2,2-

do)phenyl)-2,2-dimethylpropyl)-2-(2,2,2 trifluoroacetamido)phenyl)malonate (3a) was synthesized from **2a** following **Procedure 5**. Crude material was purified by silica chromatography (0→30→60% EtOAc/Hex) to yield the desired product as a white solid (0.9775 g, 66% yield, 94:6 er). The product is isolated as a 1.0:1 mixture of diastereomers. **TLC** (30% EtOAc/Hex): $R_f = 0.42$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3382, 2952, 2866, 2287, 2124, 1721, 1531, 1281, 1152, 1028, 759.

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 10.22 (s, 1H), 8.41 (s, 1H), 8.20 (dd, $J = 8.5, 2.3$ Hz, 1H), 7.79 (d, $J = 8.4$ Hz, 1H), 7.60 (d, $J = 1.7$ Hz, 1H), 7.48 (dt, $J = 8.4, 2.0$ Hz, 2H), 7.43 (d, $J = 8.6$ Hz, 1H), 7.22 (d, $J = 1.6$ Hz, 1H), 6.93 (d, $J = 7.4$ Hz, 1H), 6.46 (d, $J = 7.9$ Hz, 2H), 4.62 (s, 1H), 4.32 – 4.03 (m, 4H), 3.68&3.68 (s*, 1H), 3.56 (brs, 2H), 2.46 (td, $J = 7.5, 2.8$ Hz, 2H), 2.13 (s, 3H), 1.71 – 1.50 (m, 4H), 1.24 (t, $J = 7.1$ Hz, 3H), 1.01&1.01 (s*, 9H). (Note: *indicates overlap of two diastereomeric singlets that may appear as an apparent doublet)


$^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 168.9, 168.8, 168.8, 168.7, 155.6 (q, $J = 37.3$ Hz), 154.7 (q, $J = 37.7$ Hz), 144.6, 142.1&142.1, 141.0 &141.0, 140.7, 133.8, 133.7&133.7, 132.6, 131.6, 130.5, 130.4, 129.9&129.8, 125.9, 125.6, 121.7&121.7, 120.0&120.0, 118.8, 116.1 (q, $J = 288.4$ Hz), 115.7 (q, $J = 288.4$ Hz), 115.1, 114.0, 66.9&66.9, 63.0&63.0, 62.9&62.9, 57.5, 35.4, 34.9, 29.2, 27.9&27.8, 27.4&27.4, 17.0, 13.9.

$^{19}\text{F NMR}$ (471 MHz, CDCl_3) δ -75.83, -76.03.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{37}\text{H}_{40}\text{BrF}_6\text{N}_3\text{O}_6+\text{H}]^+$ requires $m/z = 818.2065$, found $m/z = 818.2075$.

Optical Rotation: $\alpha_D^{20} = +15.6^\circ$ ($c = 0.5$, MeOH, 94:6 er)

HPLC (Chiralpak® AD-H column, 10% IPA/Hexanes eluent, 1.00 mL min^{-1} flow rate, 25 $^\circ\text{C}$, 250 nm, 1.0:1 dr): major diastereomers $t_R = 21.3$ min, 29.9 min; minor diastereomers $t_R = 23.5$ min, 34.1 min.



1-(4-(3-aminophenyl)butyl) 3-ethyl 2-(5-((R)-1-(3-bromo-4-(2,2,2-trifluoroacetamido)phenyl)-2,2-dimethylpropyl)-2-(2,2,2-trifluoroacetamido)phenyl)malonate (3b) was

synthesized from **2b** following **Procedure 5**. Crude material was purified by silica chromatography (0→30→60% EtOAc/Hex) to yield the desired product as a white solid (0.9392 g, 65% yield, 94:6 er). The product is isolated as a 1.0:1 mixture of diastereomers. **TLC** (30% EtOAc/Hex): $R_f = 0.39$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3378, 2951, 2288, 2110, 1721, 1531, 1281, 1151, 1027, 903, 606.

$^1\text{H NMR}$ (600 MHz, CDCl_3): δ 10.21 (s, 1H), 8.40 (s, 1H), 8.20 (d, $J = 8.6$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 1H), 7.59 (s, 1H), 7.47 (d, $J = 8.3$ Hz, 1H), 7.43 (d, $J = 8.5$ Hz, 1H), 7.20 (s, 1H), 7.04 (t, $J = 7.7$ Hz, 1H), 6.52 (d, $J = 7.7$ Hz, 2H), 6.47 (s, 1H), 4.61 (s, 1H), 4.34 – 4.04 (m, 4H), 3.67 (s, 1H), 2.47 (t, $J = 7.3$ Hz, 2H), 1.70 – 1.46 (m, 4H), 1.23 (t, $J = 7.1$ Hz, 3H), 1.00 (s, 9H).


$^{13}\text{C NMR}$ (151 MHz, CDCl_3): δ 168.9, 168.8, 168.8, 168.7, 155.7 (q, $J = 37.2$ Hz), 154.8 (q, $J = 37.7$ Hz), 146.2, 143.2, 142.1&142.1, 141.0&141.0, 133.8, 133.7, 132.7, 131.6, 130.5&130.4, 129.9&129.9, 129.4, 125.9, 125.7, 121.7, 119.1, 116.1 (q, $J = 289.9$ Hz), 115.7 (q, $J = 288.4$ Hz), 115.5, 114.0, 113.1, 66.9&66.8, 63.1&63.1, 63.0&63.0, 57.6, 35.5, 35.3, 29.2, 27.9&27.9, 27.3&27.3, 14.0.

$^{19}\text{F NMR}$ (471 MHz, CDCl_3) δ -75.82, -76.03.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{36}\text{H}_{38}\text{BrF}_6\text{N}_3\text{O}_6 + \text{H}]^+$ requires $m/z = 804.1908$, found $m/z = 804.1922$.

Optical Rotation: $\alpha_D^{20} = +15.0^\circ$ ($c = 0.5$, MeOH, 94:6 er)

HPLC: (Chiralpak® AD-H column, 10% IPA/Hexanes eluent, 1.00 mL min^{-1} flow rate, 25°C , 250 nm, 1.0:1 dr): major diastereomers $t_R = 22.6$ min, 30.3 min; minor diastereomers $t_R = 25.3$ min, 38.1 min.



1-(4-(4-amino-1-methoxynaphthalen-2-yl)butyl) 3-ethyl 2-(5-((R)-1-(3-bromo-4-(2,2,2-trifluoroacetamido)phenyl)-2,2-dimethylpropyl)-2-(2,2,2-trifluoroacetamido)phenyl)malonate (3c) was synthesized from **2c** following **Procedure 5**. Crude material was purified by silica chromatography (0→35→75% EtOAc/Hex) to yield the desired product as a beige solid (1.1229g, 71% yield, 94:6 er). The product is isolated as a 1.0:1 mixture of diastereomers.

TLC (30% EtOAc/Hex): $R_f = 0.43$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3309, 2952, 2110, 1722, 1531, 1281, 1152, 1030, 764, 606.

$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 10.23 (s, 1H), 8.38 (s, 1H), 8.16 (dd, $J = 8.5, 5.6$ Hz, 1H), 8.03 (d, $J = 8.2$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 2H), 7.57 (s, 1H), 7.52 – 7.36 (m, 4H), 7.20 (s, 1H), 6.54 (s, 1H), 4.62&4.62 (s*, 1H), 4.32 – 4.12 (m, 4H), 3.98 (brs, 2H), 3.82 (s, 3H), 3.65&3.64 (s*, 1H), 2.68 (t, $J = 7.4$ Hz, 2H), 1.79 – 1.53 (m, 4H), 1.22 (t, $J = 6.8$ Hz, 3H), 0.98&0.95 (s*, 9H). (Note: *indicates overlap of two diastereomeric singlets that may appear as an apparent doublet)


$^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 168.9, 168.8, 168.8, 168.7, 155.7 (q, $J = 37.8$ Hz), 154.8 (q, $J = 37.8$ Hz), 146.4, 142.1&142.1, 141.1&141.0, 138.5&138.5, 133.8, 133.7&133.7, 132.7, 131.6, 130.5&130.4, 130.3, 129.9&129.8, 128.6, 126.1&126.1, 125.9, 125.7, 124.7&124.7, 123.9, 122.7, 121.8, 121.4, 116.1 (q, $J = 288.4$ Hz), 115.7 (q, $J = 289.9$ Hz), 114.0, 111.5&111.5, 66.9&66.8, 63.1&63.0, 63.0, 62.2, 57.6, 35.4, 29.2&29.1, 29.1&29.1, 28.1&28.1, 26.8&26.8, 14.0.

$^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -75.83, -75.84, -76.04.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{41}\text{H}_{42}\text{BrF}_6\text{N}_3\text{O}_7 + \text{H}]^+$ requires $m/z = 884.2172$, found $m/z = 884.2190$.

Optical Rotation: $\alpha_D^{20} = +12.9^\circ$ ($c = 0.5$, MeOH, 94:6 er)

HPLC (Chiralpak® IB column, 6% EtOH/Hexanes eluent, 1.10 mL min^{-1} flow rate, 250 nm, 25 °C, 1.0:1 dr): major diastereomers $t_R = 42.7$ min, 51.0 min; minor diastereomers $t_R = 29.9$ min, 32.2 min.



1-(4-(5-amino-2-methoxyphenyl)butyl) 3-ethyl 2-(5-((*R*)-1-(3-bromo-4-(2,2,2-trifluoroacetamido)phenyl)-2,2-dimethylpropyl)-2-(2,2,2-trifluoroacetamido)phenyl)malonate (3d) was

synthesized from **2d** following **Procedure 5**. Crude material was purified by silica chromatography (0→40→85% EtOAc/Hex) to yield the desired product as a pale pink solid (1.0358 g, 69% yield, 92:8 er). The product is isolated as a 1.0:1 mixture of diastereomers.

TLC (40% EtOAc/Hex): $R_f = 0.53$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3373, 2952, 2872, 2117, 1720, 1530, 1281, 1152, 1030, 733.

$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 10.22 (s, 1H), 8.42 (d, $J = 11.5$ Hz, 1H), 8.19 (dd, $J = 8.4, 4.8$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 1H), 7.59 (s, 1H), 7.47 (d, $J = 8.2$ Hz, 1H), 7.43 (d, $J = 8.4$ Hz, 1H), 7.21 (s, 1H), 6.65 (d, $J = 8.5$ Hz, 1H), 6.51 (d, $J = 8.4$ Hz, 1H), 6.46 (s, 1H), 4.62 (s, 1H), 4.29 – 4.10 (m, 4H), 3.71 (s, 3H), 3.67 (s, 1H), 3.28 (brs, 2H), 2.50 (t, $J = 7.4$ Hz, 2H), 1.63 (q, $J = 6.6$ Hz, 2H), 1.57 – 1.49 (m, 2H), 1.23 (t, $J = 7.1$ Hz, 3H), 1.01 & 1.00 (s*, 9H). (Note: * indicates overlap of two diastereomeric singlets that may appear as an apparent doublet)


$^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 168.9, 168.8, 168.8, 168.7, 155.6 (q, $J = 37.3$ Hz), 154.8 (q, $J = 37.8$ Hz), 150.9, 142.1 & 142.1, 141.0, 139.7 & 139.7, 133.8, 132.7, 131.6, 131.3, 130.4, 129.9 & 129.9, 125.9, 125.6, 121.8 & 121.8, 117.8, 116.1 (q, $J = 288.4$ Hz), 115.7 (q, $J = 289.9$ Hz), 114.1, 114.0, 113.6, 111.9 & 111.9, 67.0 & 67.0, 63.0, 57.6, 56.1, 35.5, 29.6 & 29.6, 29.2, 28.0 & 28.0, 26.0 & 26.0, 14.0.

$^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -75.79, -75.81, -76.00.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{37}\text{H}_{40}\text{BrF}_6\text{N}_3\text{O}_7 + \text{H}]^+$ requires $m/z = 834.2014$, found $m/z = 834.2022$.

Optical Rotation: $\alpha_D^{20} = +14.5^\circ$ ($c = 0.5$, MeOH, 92:8 er)

HPLC (Chiralpak® AD-H column, 7% IPA/Hexanes eluent, 1.25 mL min^{-1} flow rate, 250 nm, 25 °C, 1.0:1 dr): major diastereomers $t_R = 47.1$ min, 62.3 min, minor diastereomers $t_R = 53.4$ min, 93.5 min.



1-(5-(3-aminophenyl)pentyl) 3-ethyl 2-(5-((R)-1-(3-bromo-4-(2,2,2-trifluoroacetamido)phenyl)-2,2-dimethylpropyl)-2-(2,2,2-trifluoroacetamido)phenyl)malonate (3e) was synthesized

from **2e** following **Procedure 5**. Crude material was purified by silica chromatography (0→30→60% EtOAc/Hex) to yield the desired product as a beige solid (0.7228 g, 59% yield, 90:10 er). The product is isolated as a 1.0:1 mixture of diastereomers.

TLC (30% EtOAc/Hex): $R_f = 0.38$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3374, 3310, 2952, 2864, 2104, 1722, 1530, 1281, 1152, 1028, 749.

$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 10.20 (s, 1H), 8.38 (s, 1H), 8.21 (t, $J = 8.1$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 1H), 7.60 (s, 1H), 7.48 (d, $J = 8.4$ Hz, 1H), 7.45 (d, $J = 8.6$ Hz, 1H), 7.21 (s, 1H), 7.05 (td, $J = 7.6, 2.4$ Hz, 1H), 6.55 – 6.50 (m, 2H), 6.47 (d, $J = 10.2$ Hz, 1H), 4.62 (s, 1H), 4.27 – 4.07 (m, 4H), 3.68 (s, 1H), 3.61 (brs, 2H), 2.44 (dt, $J = 11.1, 7.7$ Hz, 2H), 1.68 – 1.50 (m, 4H), 1.35 – 1.21 (m, 5H), 1.02 (s, 9H).


$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 168.8, 168.7, 155.6 (q, $J = 37.3$ Hz), 154.8 (q, $J = 37.8$ Hz), 146.5&146.5, 143.6, 142.1&142.1, 141.0, 133.8, 133.8, 132.7, 131.7, 130.5, 130.4, 129.9&129.9, 129.3, 125.9, 125.7, 121.8&121.7, 118.9, 116.1 (q, $J = 241.9$ Hz), 115.7 (q, $J = 240.7$ Hz), 115.4, 114.0&114.0, 112.8, 66.9&66.9, 63.0&63.0, 57.6&57.6, 35.8, 35.5, 30.8, 29.2, 28.2&28.2, 25.4, 14.0.

$^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -75.84, -76.05.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{37}\text{H}_{40}\text{BrF}_6\text{N}_3\text{O}_6+\text{H}]^+$ requires $m/z = 818.2065$, found $m/z = 818.2079$.

Optical Rotation: $\alpha_D^{20} = +14.6^\circ$ ($c = 0.5$, MeOH, 90:10 er)

HPLC: (Chiralpak® AD-H column, 4% EtOH/Hexanes eluent, 1.25 mL min^{-1} flow rate, 254 nm, 20 °C, 1.0:1 dr): major diastereomers $t_R = 41.8$ min, 49.9 min; minor diastereomers $t_R = 37.9$ min, 75.2 min.



1-(4-(3-amino-5-hydroxyphenyl)butyl) 3-ethyl 2-(5-((*R*)-1-(3-bromo-4-(2,2,2-trifluoroaceta
mido)phenyl)-2,2-dimethylpropyl)-2-(2,2,2-trifluoroacetamido)phenyl)malonate (3f)
 was

synthesized from **2f** following **Procedure 5** followed by **Procedure 6**. Crude material was purified by silica chromatography (0→40→80% EtOAc/Hex) to yield the desired product as a pink solid (0.4895 g, 60% yield, 93:7 er). The product is isolated as a 1.0:1 mixture of diastereomers.

TLC (50% EtOAc/Hex): $R_f = 0.46$.

IR (FT-ATR, cm^{-1} , neat): ν_{max} 3382, 2922, 2855, 2293, 1736, 1458, 1283, 1158, 1028, 908, 734.

$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 10.26 (s, 1H), 8.55 – 8.42 (m, 1H), 8.16 (dd, 1H), 7.77 (dd, $J = 8.4, 2.1$ Hz, 1H), 7.50 – 7.43 (m, 1H), 7.41 (ddd, $J = 13.6, 8.6, 1.7$ Hz, 1H), 7.21 (dd, $J = 12.4, 1.7$ Hz, 1H), 6.02 – 6.00 (m, 2H), 5.94 (d, $J = 17.1$ Hz, 1H), 4.63&4.62 (s*, 1H), 4.33 – 4.07 (m, 4H), 3.66 (s, 1H), 2.36 (dt, $J = 12.6, 7.4$ Hz, 2H), 1.58 (dq, $J = 13.8, 6.7$ Hz, 2H), 1.52 – 1.44 (m, 2H), 1.25 (td, $J = 7.1, 3.3$ Hz, 3H), 1.00&0.99 (s*, 9H). (Note: *indicates overlap of two diastereomeric singlets that may appear as an apparent doublet)


$^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 169.0, 169.0, 168.7, 168.7, 156.9&156.8, 155.8 (q, $J = 37.5$ Hz), 154.8 (q, $J = 37.8$ Hz), 147.8&147.7, 144.5&144.5, 142.2&142.1, 141.2, 133.9&133.8, 133.7, 132.5&132.5, 131.6&131.6, 130.6&130.5, 129.8&129.8, 125.9, 125.7, 122.0&121.8, 114.2&114.1, 108.2&108.1, 106.1&106.1, 100.1&100.1, 66.9&66.8, 63.1, 63.0, 57.6&57.6, 35.4&35.4, 35.0&35.0, 29.2&29.2, 27.7&27.6, 27.0&26.9, 13.96.

$^{19}\text{F NMR}$ (471 MHz, CDCl_3): -75.81, -75.82, -76.01.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{36}\text{H}_{38}\text{BrF}_6\text{N}_3\text{O}_7 + \text{H}]^+$ requires $m/z = 820.1857$, found $m/z = 820.1890$.

Optical Rotation: $\alpha_D^{20} = +13.1^\circ$ ($c = 0.5$, MeOH, 93:7 er)

HPLC (Chiralpak® AD-H column, 16% IPA/Hexanes eluent, 1.25 mL min^{-1} flow rate, 250 nm, 25 °C, 1.0:1 dr): major diastereomers $t_R = 12.2$ min, 19.4 min; minor diastereomers $t_R = 13.9$ min, 28.0 min.



1-(4-(3-amino-5-((*tert*-butyldimethylsilyl)oxy)phenyl)butyl) 3-ethyl 2-(5-(1-(3-bromo-4-(2,2,2-trifluoroacetamido)phenyl)-2,2-dimethylpropyl)-2-(2,2,2-trifluoroacetamido)phenyl)

malonate (S23) was prepared from **3f** using **Procedure 4**. Crude material was purified by silica chromatography (0→25→60% EtOAc/Hex) to yield **S23** as a white solid (0.1007 g, 54% yield). **S23** was synthesized to prepare the authentic standard of **4f**.

TLC (30% EtOAc/Hex): $R_f = 0.44$.


IR (FT-ATR, cm^{-1} , neat): ν_{max} 3436, 3233, 2931, 2860, 2115, 1728, 1660, 1387, 1255, 1153, 1094, 838, 660.

^1H NMR (500 MHz, CDCl_3) δ 10.22 (s, 1H), 8.42 (s, 1H), 8.19 (d, $J = 8.5$ Hz, 1H), 7.78 (d, $J = 8.3$ Hz, 1H), 7.60 (s, 1H), 7.52 – 7.46 (m, 1H), 7.44 (d, $J = 8.5$ Hz, 1H), 7.22 (s, 1H), 6.08 (s, 1H), 6.05 (s, 1H), 6.03 (s, 1H), 4.63 (s, 1H), 4.27 – 4.08 (m, 4H), 3.68 (s, 1H), 3.57 (brs, 2H), 2.41 (t, $J = 7.1$ Hz, 2H), 1.66 – 1.59 (m, 2H), 1.57 – 1.49 (m, 2H), 1.23 (t, $J = 7.1$ Hz, 3H), 1.01 (s, 9H), 0.97 (s, 9H), 0.18 (s, 6H).

^{13}C NMR (126 MHz, CDCl_3) δ 168.9, 168.8, 168.8, 168.7, 156.7, 155.6 (q, $J = 37.3$ Hz), 154.7 (q, $J = 37.7$ Hz), 147.5, 144.1, 142.1&142.1, 141.0, 133.8, 133.7, 132.6, 131.6, 130.5&130.4, 129.9&129.8, 125.9, 125.6, 121.8, 116.1 (q, $J = 288.5$ Hz), 115.7 (q, $J = 288.5$ Hz), 114.0&114.0, 110.9, 108.8, 104.9, 66.9&66.8, 63.0&63.0, 62.9&62.9, 57.5, 35.4, 35.3, 29.1, 27.8&27.8, 27.2&27.2, 25.8, 18.3, 13.9, -4.3.

^{19}F NMR (471 MHz, CDCl_3) δ -75.82, -75.83, -76.02.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{42}\text{H}_{52}\text{BrF}_6\text{N}_3\text{O}_7\text{Si} + \text{H}]^+$ requires $m/z = 932.2740$, found $m/z = 932.2746$.



1-(3-(3-aminophenyl)propyl) 3-ethyl 2-(5-(1-(3-bromo-4-(2,2,2-trifluoroacetamido)phenyl)-2,2-dimethylpropyl)-2-(2,2,2-trifluoroacetamido)phenyl)malonate (S24) was synthesized from S17 following **Procedure 4**. Crude material was purified by silica chromatography (0→40→80% EtOAc/Hex) to yield the desired product as a white solid (0.3641 g, 67% yield).

TLC (30% EtOAc/Hex): R_f = 0.42.


IR (FT-ATR, cm⁻¹, neat): ν_{\max} 3383, 2962, 2204, 2103, 1720, 1604, 1531, 1281, 1153, 1027, 734.

¹H NMR (400 MHz, CDCl₃) δ 10.24 (s, 1H), 8.40 (s, 1H), 8.17 (t, J = 8.1 Hz, 1H), 7.85 – 7.77 (m, 1H), 7.60 (dd, J = 5.5, 1.9 Hz, 1H), 7.53 – 7.48 (m, 1H), 7.47 – 7.41 (m, 1H), 7.25 (dd, J = 4.9, 2.6 Hz, 2H), 7.02 (td, J = 7.7, 3.7 Hz, 1H), 6.53 – 6.49 (m, 1H), 6.48 – 6.43 (m, 1H), 6.36 (d, J = 8.3 Hz, 1H), 4.65&4.65 (s*, 1H), 4.32 – 4.06 (m, 4H), 3.73 (brs, 2H), 3.70 (s, 1H), 2.44 (q, J = 7.5 Hz, 2H), 1.93–1.79 (m, 2H), 1.25 (t, J = 7.1, 3H), 1.03&1.02 (s*, 9H). (Note: *indicates overlap of two diastereomeric singlets that may appear as an apparent doublet)

¹³C NMR (101 MHz, CDCl₃) δ 168.8, 168.8, 168.7, 155.7 (q, J = 37.4 Hz), 154.7 (q, J = 38.0 Hz), 146.4&146.3, 142.1, 141.9, 141.1&141.1, 133.8&133.7, 133.7, 132.6&132.6, 131.6&131.6, 130.5&130.4, 129.8&129.8, 129.5&129.4, 125.9, 125.7&125.7, 121.8, 118.9, 116.1 (q, J = 289.9 Hz), 115.7 (q, J = 289.9 Hz), 115.4, 114.1, 113.2, 66.0, 63.1, 63.0, 57.5, 35.4&35.4, 31.7&31.7, 29.7, 29.2, 14.0.

¹⁹F NMR (376 MHz, CDCl₃) δ -75.84, -76.04.

HRMS (ESI/Q-TOF): Exact mass calculated for [C₃₅H₃₆BrF₆N₃O₆ + H]⁺ requires m/z = 790.1751, found m/z = 790.1746.



1-(4-(2-aminophenyl)butyl) 3-ethyl 2-(5-(1-(3-bromo-4-(2,2,2-trifluoroacetamido)phenyl)-2,2-dimethylpropyl)-2-(2,2,2-trifluoroacetamido)phenyl)malonate (S25) was synthesized from **S18** following **Procedure 4**. Crude material was purified by silica chromatography (0→30→60% EtOAc/Hex) to yield the desired product as a white solid.

Yield: 84% (0.1347 g)

TLC (30% EtOAc/Hex): R_f =0.39.


IR (FT-ATR, cm^{-1} , neat): ν_{max} 3386, 3021, 2966, 1968, 1737, 1531, 1283, 1215, 1158, 1030, 903, 667.

^1H NMR (600 MHz, CDCl_3) δ 10.21 (s, 1H), 8.40 (s, 1H), 8.19 (d, J = 8.5 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.59 (s, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.22 (brs, 1H), 7.02 (t, J = 7.6 Hz, 1H), 6.98 – 6.93 (m, 1H), 6.70 (td, J = 7.4, 3.9 Hz, 1H), 6.65 (d, J = 7.9 Hz, 1H), 4.64&4.63 (s*, 1H), 4.31 – 4.10 (m, 4H), 3.68&3.67 (s*, 1H), 3.43 (brs, 2H), 2.43 (t, J = 7.7 Hz, 2H), 1.68 (p, J = 6.6 Hz, 2H), 1.57 (p, J = 7.4 Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H), 1.01&1.00 (s*, 9H). (Note: *indicates overlap of two diastereomeric singlets that may appear as an apparent doublet)

^{13}C NMR (151 MHz, CDCl_3): δ 168.9, 168.9, 168.8, 168.7, 155.7 (q, J = 37.8 Hz), 154.8 (q, J = 37.8 Hz), 144.1, 142.1&142.0, 141.1&141.1, 133.7, 133.7, 132.6, 131.6, 130.5&130.4, 129.9& 129.8, 129.5&129.5, 127.2&127.2, 126.0&126.0, 125.8&125.7, 121.7, 118.9&118.9, 116.1 (q, J = 288.4 Hz), 115.8*, 115.8*, 115.7 (q, J = 288.4 Hz), 114.0*, 114.0*, 66.7*, 66.7*, 63.1*, 63.1*, 63.0&62.9, 57.5&57.5, 35.4, 30.7, 29.2&29.1, 28.2&28.2, 24.8, 13.9.

^{19}F NMR (471 MHz, CDCl_3): δ -75.83, -76.03.

HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{36}\text{H}_{38}\text{BrF}_6\text{N}_2\text{O}_6 + \text{H}]^+$ requires m/z = 804.1908, found m/z = 804.1905.



S26

1-(5-(2-aminophenyl)pentyl) 3-ethyl 2-(5-(1-(3-bromo-4-(2,2,2-trifluoroacetamido)phenyl)-2,2-dimethylpropyl)-2-(2,2,2-trifluoroacetamido)phenyl)malonate (S26) was synthesized from **S19** following **Procedure 4**. Crude material was purified by silica chromatography (0→30→60% EtOAc/Hex) to yield the desired product as a white solid (0.4192 g, 60% yield).

TLC (40% EtOAc/Hex): $R_f = 0.59$.



IR (FT-ATR, cm^{-1} , neat): ν_{max} 3384, 2952, 2864, 2381, 2201, 1982, 1720, 1531, 1281, 1151, 1028, 750.


$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 10.23 (s, 1H), 8.39 (d, $J = 9.5$ Hz, 1H), 8.20 (t, $J = 7.6$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 1H), 7.60 (s, 1H), 7.48 (d, $J = 8.3$ Hz, 1H), 7.44 (d, $J = 8.5$ Hz, 1H), 7.22 (s, 1H), 7.05 – 7.00 (m, 1H), 6.98 (t, $J = 6.6$ Hz, 1H), 6.72 (t, $J = 6.8$ Hz, 1H), 6.68 – 6.63 (m, 1H), 4.63 (s, 1H), 4.28 – 4.07 (m, 4H), 3.68 (s, 1H), 3.06 (brs, 2H), 2.47 – 2.36 (m, 2H), 1.66 – 1.51 (m, 4H), 1.35 – 1.28 (m, 2H), 1.27 – 1.22 (m, 3H), 1.02 (s, 9H).

$^{13}\text{C NMR}$ (151 MHz, CDCl_3): δ 168.9, 168.8, 168.8, 168.7, 155.6 (q, $J = 37.4$ Hz), 154.8 (q, $J = 37.7$ Hz), 144.1, 142.1&142.1, 141.0, 133.8&133.8, 133.8, 132.6, 131.6, 130.5&130.4, 129.9&129.8, 129.5, 127.1, 126.5, 125.9, 125.7, 121.8&121.7, 118.9, 116.1 (q, $J = 288.4$ Hz), 115.7 (q, $J = 288.4$ Hz), 115.8, 114.1&114.0, 66.8, 63.1, 63.0, 57.6, 35.5, 31.2, 29.2, 28.2, 25.7, 14.0.


$^{19}\text{F NMR}$ (471 MHz, CDCl_3) δ -75.82, -76.03.


HRMS (ESI/Q-TOF): Exact mass calculated for $[\text{C}_{37}\text{H}_{40}\text{BrF}_6\text{N}_2\text{O}_6 + \text{H}]^+$ requires $m/z = 815.2065$, found $m/z = 815.2059$.








3a
(¹⁹F NMR, CDCl₃, 471 MHz)














3b
(¹⁹F NMR, CDCl₃, 471 MHz)














3c
(¹⁹F NMR, CDCl₃, 376 MHz)














3d
(¹⁹F NMR, CDCl₃, 376 MHz)














3e
(¹⁹F NMR, CDCl₃, 376 MHz)














3f
(¹⁹F NMR, CDCl₃, 500 MHz)














S23
(¹⁹F NMR, CDCl₃, 471 MHz)















S24
(¹⁹F NMR, CDCl₃, 376 MHz)

-75.84
-76.04















S25
(¹⁹F NMR, CDCl₃, 471 MHz)














8.5 HPLC Traces of Linear Precursors (3a-3f)





3a

Chiralpak AD-H
10% IPA/Hexanes, 1.00 mL/min, 25 °C, 250 nm






Recovered SM (3a) after macrocyclization with mismatched ligand L2




**3b**



Chiralpak AD-H

10% IPA/Hexanes, 1.00 mL/min, 25 °C, 250 nm


**Recovered 3b after macrocyclization with mismatched ligand L2**




3c
Chiralpak AD-H
6% EtOH/Hexanes, 1.200 mL/min, 25 °C, 250 nm






3d
Chiralpak AD-H
7% IPA/Hexanes, 1.250 mL/min, 25 °C, 250 nm







3e
Chiralpak AD-H
4% EtOH/Hexanes, 1.25 mL/min, 25 °C, 254 nm




3f
Chiralpak AD-H
16% IPA/Hexanes, 1.25 mL/min, 25 °C, 250 nm



9. Reaction Optimizations and Procedures for Macrocyclization via Cu-catalyzed intramolecular C–N cross-coupling

9.1 Procedure 7: Protocols for Small-Scale Intramolecular Ullmann cross-coupling



To an oven dried two-dram vial equipped with magnetic stir bar was added Cu(I) source (0.007 mmol, 0.10 equiv), peptide ligand (0.014 mmol, 0.20 equiv) and flame-dried K_3PO_4 (0.294 mmol, 4.20 equiv). The flask was sealed with a septa cap and further secured with Teflon tape. The flask was sparged with N_2 for 10 minutes. Diarylmethane (0.07 mmol, 1.00 equiv) was added to a separate oven dried dram vial and sparged with N_2 for 5 minutes. The vials were taken into the glove box. A 1:2 DMF/MeCN solution (0.36 mL, 0.19 M) was added to the vial containing Cu(I). The resulting reaction mixture was left to stir for 10 minutes. Diarylmethane was dissolved in a 1:2 DMF/MeCN solution (0.1 mL) and added to the mixture. The vial was further rinsed with DMF/MeCN (0.1 mL) and added to the stirring mixture. The reaction mixture was capped and secured with Teflon tape, then left to stir for 15 h at the indicated temperature. After 15 h, the reaction mixture was diluted with EtOAc and transferred to a separatory funnel. The organic layer was washed with a solution of saturated NH_4Cl (aq). The organic layer was separated and the aqueous layer was extracted with EtOAc \times 3. Combined organic layers were washed with sat. NaCl (aq). The combined organic layers were then dried over anhydrous Na_2SO_4 , filtered, and concentrated in vacuo. Percent yield was determined via ^1H NMR by comparing the relative integration of malonate peak of the desired product to an internal NMR standard of 1,4-bis(trimethylsilyl)benzene (see Figure S1).






Figure S1. Sample of Determination of NMR yield.

9.2 Identification of Optimal Model Substrates^{a,b,c}



a) Reactions were executed according to **Procedure 7**. b) Yield was determined using ^1H NMR by comparing to an internal NMR standard 1,4-bis(trimethylsilyl)benzene. c) Linear precursors were prepared using **Procedure 5**.


9.3 Table S2: Cu(I) Screen



Entry ^a	Cu (I)	Temp (°C)	Yield (%) ^b
1	CuBr	45	44
2	CuBr	23	47
3	CuI	45	39
4	CuI	23	48
5	Cu(MeCN) ₄ BF ₄	45	36

a) Reactions were executed according to **Procedure 7**. b) Yield was determined using ^1H NMR by comparing to an internal standard 1,4-bis(trimethylsilyl)benzene. c) **2b** was prepared using *ent*-**L1** following **Procedure 6**. In the main text, **2b** was prepared using **L1**.


9.4 Table S3: Concentration Effects



Entry ^a	Concentration (M)	Yield (%) ^b
1	0.25	17
2	0.125	44
3	0.06	33
4	0.05	23
5	0.01	9

a) Reactions were executed according to **Procedure 7**. b) Yields were determined using ^1H NMR by comparing to an internal standard 1,4-bis(trimethylsilyl)benzene. c) **2b** was prepared using *ent*-**L1** following **Procedure 6**. In the main text, **2b** was prepared using **L1**.


9.5 Table S4: Temperature & Copper Loading



Entry ^{a,c}	Cu(I) (mol %)	Temp (°C)	Yield (%) ^{b,d}
1	CuBr (5 mol %)	45	34
2	CuBr (10 mol %)	45	44
3	CuBr (10 mol %)	23	47
3	CuBr (20 mol %)	45	50
4	CuBr (20 mol %)	23	61
5	CuBr (20 mol %)	30	60


a) Reactions were executed according to **Procedure 7**. b) Yield was determined using ^1H NMR by comparing to an internal standard 1,4-bis(trimethylsilyl)benzene. c) All reactions carried out with 1:2 ratio of Cu(I):peptide ligand based on previous optimization.² d) Reaction proceeds at room temperature, but 45 °C was chosen as the optimal condition due to most consistent reproducibility outside the glovebox.

10. Procedure 8: Macrocyclization of Diarylmethanes Under Optimized Conditions



K_3PO_4 (0.1401 g, 0.66 mmol, 4.40 equiv) was flamed-dried under vacuum in a 5-mL Schlenk flask. Upon cooling to room temperature, CuBr (0.0043 g, 0.03 mmol, 0.20 equiv), peptide ligand (0.06 mmol, 0.40 equiv) and a magnetic stir bar were added to the flask. The flask was sealed with a new rubber septum and further secured with Parafilm®. The flask was evacuated for 5 minutes and backfilled with N_2 . This process was repeated two additional times. 1:2 DMF/MeCN mixture (0.8 mL) was added through the septum, and the mixture was allowed to stir for 15 min at room temperature, after which diarylmethane **3a-f** (0.15 mmol, 1.00 equiv) in MeCN (0.2 mL) was added. The vial was rinsed with DMF (0.2 mL) which was also added to the reaction mixture. The reaction mixture was left to stir for 15 h at 45 °C. After 15 h, the reaction mixture was diluted with EtOAc (10 mL) and transferred to a separatory funnel. The organic layer washed with saturated NH_4Cl (aq) (10 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (5 mL \times 3). Combined organic layers were washed with sat. NaCl (aq) (30 mL), dried over Na_2SO_4 , filtered, and concentrated in vacuo. The crude material was purified by flash chromatography with EtOAc/Hex gradient.


11. Kinetic Resolution of Diarylmethanes Under Optimized Conditions




Reactions were executed according to **Procedure 8** for the indicated time.

HPLC Conditions: Chiralpak® AD-H column, 10% IPA/Hex eluent, 1.00 mL/min flow rate, 25 °C, 250 nm.
See SI section 8.5 for racemic standard.

MWD1 D, Sig=250,4 Ref=off (JH/JH-1-168_AD-H 2021-04-14 16-02-401FC-0101.D)




MWD1 D, Sig=250,4 Ref=off (JH/JH-1-168_AD-H 2021-04-15 17-24-591FC-0101.D)




HPLC Conditions: Chiralpak® IB column, 55% MeCN/H₂O eluent with 0.5% formic acid buffer, 1.25 mL min⁻¹ flow rate, 25 °C, 265 nm. See SI section 12.1 for racemic standard.


DAD1 B, Sig=265,4 Ref=360,100 (JH/JH-I-168 2021-04-15 17-04-371035-0201.D)



DAD1 B, Sig=265,4 Ref=360,100 (JH/JH-I-168 2021-04-15 17-04-371034-0101.D)



12. Characterization and Spectra of Macrocyclic Products (4a-4f, 5f)



Ethyl (4*R*)-4-(*tert*-butyl)-1⁵-methyl-7-oxo-3⁶,5⁴-bis(2,2,2-trifluoroacetamido)-8-oxa-2-aza-1,3,5(1,3)-tribenzenacyclododecaphane-6-carboxylate (4a) was synthesized from **3a** following **Procedure 8**. Crude material was purified by silica chromatography (0→20→85% EtOAc/Hex) to yield the desired product as a white solid. **4a** is observed as a 1.7:1 mixture of diastereomers CD₂Cl₂ at 25 °C by ¹H NMR.

Yield: 67% (0.0740 g) using *ent*-L2

TLC (30% EtOAc/Hex): R_f = 0.86, 0.81.

IR (FT-ATR, cm⁻¹, neat): ν_{max} 3245, 2964, 2254, 1723, 1533, 1402, 1285, 1159, 904, 723.

¹H NMR (500 MHz, CD₂Cl₂): **major diastereomer:** δ 10.29 (s, 1H), 8.71 (s, 1H), 8.06 (d, *J* = 8.5 Hz, 1H), 7.75 – 7.64 (m, 2H)*, 7.47 (dd, *J* = 8.5, 2.0 Hz, 1H), 7.17 (d, *J* = 1.8 Hz, 1H), 7.07 (d, *J* = 1.6 Hz, 1H), 7.06 – 7.00 (m, 1H)*, 6.58 (dd, *J* = 7.5, 1.3 Hz, 1H)*, 5.95 (s, 1H)*, 5.09 (s, 1H), 4.59 (s, 1H), 4.32 – 4.12 (m, 3H)*, 4.01 – 3.93 (m, 1H), 3.81 (s, 1H), 3.70 (s, 1H), 2.32 – 2.18 (s + m, 5H)*, 1.59 – 1.38 (m, 2H)*, 1.28 (t, *J* = 7.1 Hz, 3H), 1.19 – 1.09 (m, 2H)*, 1.06 (s, 9H)*; **minor diastereomer:** δ 10.08 (s, 1H), 8.55 (s, 1H), 8.15 (d, *J* = 8.5 Hz, 1H), 7.75 – 7.64 (m, 1H)*, 7.52 (dd, *J* = 8.5, 1.8 Hz, 1H), 7.38 (dd, *J* = 8.3, 2.0 Hz, 1H), 7.26 (d, *J* = 1.7 Hz, 1H), 7.21 (d, *J* = 1.8 Hz, 1H), 7.06 – 7.00 (m, 1H)*, 6.58 (dd, *J* = 7.5, 1.3 Hz, 1H)*, 5.95 (s, 1H)*, 5.13 (s, 1H), 4.61 (s, 1H), 4.32 – 4.12 (m, 3H)*, 4.11 – 4.02 (m, 1H), 3.81 (s, 1H), 2.32 – 2.18 (s + m, 5H)*, 1.59 – 1.38 (m, 2H)*, 1.23 (t, *J* = 7.1 Hz, 3H), 1.19 – 1.09 (m, 2H)*, 1.06 (brs, 9H)*. (* Indicates overlap of peaks corresponding to the major and minor diastereomers.)


¹³C NMR (151 MHz, CD₂Cl₂): **major diastereomer:** δ 169.8, 169.1, 155.9–154.6 (m, overlapping quartets of C=O(CF₃)), 144.1, 142.5, 142.3, 141.8, 135.4, 134.0, 132.6, 130.8, 130.0, 129.1*, 128.9, 127.0, 126.5, 125.7, 122.8 (q, *J* = 288.4 Hz), 116.1 (q, *J* = 288.4 Hz), 122.6, 121.6, 121.1, 114.1, 66.7, 63.4, 63.2, 57.8, 35.8, 35.4, 29.4, 28.7, 28.6, 17.3*, 14.1; **minor diastereomer**:** δ 169.2, 169.2, 155.9–154.6 (m, overlapping quartets of C=O(CF₃)), 143.9, 142.7, 142.0, 141.7, 133.6, 132.5, 132.2, 130.8, 130.6, 129.1*, 128.5, 127.8, 126.5, 125.4, 122.7, 121.6, 121.4, 113.8, 66.2, 63.5, 63.2, 57.5, 35.2, 35.1, 29.4, 28.1, 28.0, 17.3*, 14.0. (Note: * indicates overlap of peaks corresponding multiple peaks; ** peaks corresponding to (C=O)CF₃ for the minor diastereomer were not observed at the signal-to-noise ratio of the measurement.)

¹⁹F NMR (471 MHz, CD₂Cl₂): δ -76.17, -76.52, -76.52, -76.54.

HRMS: Exact mass calculated for [C₃₇H₃₉F₆N₃O₆ + H]⁺ requires *m/z* = 736.2816, found *m/z* = 736.2832.

Optical Rotation: α_D²⁰ = + 69.5 ° (*c* = 0.5, MeOH, >99:1 er)

HPLC (Chiralpak® IB column, 55% MeCN/H₂O eluent with 0.5% formic acid buffer, 1.25 mL min⁻¹ flow rate, 25 °C, 265 nm, observed as 1.9:1 dr): major diastereomers t_R = 20.8 min, 34.4 min; minor diastereomers t_R = 22.5 min, 32.7 min.



Ethyl (4R)-4-(tert-butyl)-7-oxo-3,5-bis(2,2,2-trifluoroacetamido)-8-oxa-2-aza-1,3,5(1,3)-tribenzenacyclododecaphane-6-carboxylate (4b) was synthesized from **3b** following **Procedure 8**. Crude material was purified by silica chromatography (0→25→75% EtOAc/Hex) to yield the desired product as a white solid. **4b** is observed as a 2.5:1 mixture of diastereomers CD₂Cl₂ at 25 °C by ¹H NMR.

Yield: 50% (0.0536 g) using *ent-L2*

TLC (30% EtOAc/Hex): R_f = 0.80.

IR (FT-ATR, cm⁻¹, neat): ν_{\max} 3331, 2952, 2867, 2119, 1717, 1501 1532, 1283, 1196, 1152, 906, 727.

¹H NMR (500 MHz, CD₂Cl₂): **major diastereomer:** δ 10.29 (s, 1H), 8.75 (s, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.69 – 7.62 (m, 1H)*, 7.49 (dd, J = 8.5, 1.8 Hz, 1H), 7.24 – 7.19 (m, 1H)*, 7.17 – 7.12 (m, 1H)*, 7.07 (d, J = 1.9 Hz, 1H), 6.80 – 6.75 (m, 1H)*, 6.70 – 6.64 (m, 1H)*, 6.04 (s, 1H), 5.23 (s, 1H), 4.60 (s, 1H), 4.32 – 4.13 (m, 3H)*, 3.97 (ddd, J = 11.0, 7.2, 4.0 Hz, 1H), 3.69 (s, 1H), 2.39 – 2.19 (m, 2H)*, 1.52 – 1.41 (m, 2H)*, 1.28 (t, J = 7.1 Hz, 3H), 1.20 – 1.11 (m, 2H)*, 1.05 (s, 9H); **minor diastereomer:** δ 10.05 (s, 1H), 8.67 (s, 1H), 8.17 (d, J = 8.5 Hz, 1H), 7.69 – 7.62 (m, 1H)*, 7.52 (dd, J = 8.5, 1.8 Hz, 1H), 7.38 (dd, J = 8.3, 1.9 Hz, 1H), 7.27 (d, J = 1.8 Hz, 1H), 7.24 – 7.19 (m, 1H)*, 7.17 – 7.12 (m, 1H)*, 6.80 – 6.75 (m, 1H)*, 6.70 – 6.64 (m, 1H)*, 6.01 (s, 1H), 5.33 (s, 1H), 4.61 (s, 1H), 4.32 – 4.13 (m, 3H)*, 4.10 – 4.01 (m, 1H), 3.80 (s, 1H), 2.39 – 2.19 (m, 2H)*, 1.52 – 1.41 (m, 2H)*, 1.24 (t, J = 7.1 Hz, 3H), 1.20 – 1.11 (m, 2H)*, 1.05 (s, 9H). (Note: * indicates overlap of peaks corresponding to the major and minor diastereomers.)


¹³C NMR (151 MHz, CD₂Cl₂) **major diastereomer:** δ 169.7, 169.1, 155.5 (q, J = 64.9 Hz), 155.2 (q, J = 64.9 Hz), 146.1, 144.3, 142.5, 135.3, 133.9, 132.6, 132.5, 130.2, 129.6,* 129.2, 128.5, 126.9, 126.4, 125.6, 121.5, 121.4, 116.4 (q, J = 288.4 Hz), 116.1 (q, J = 288.4 Hz), 115.4, 114.5, 66.7, 63.5, 63.4, 57.8, 35.9, 35.4, 29.4*, 28.6, 28.2, 14.0; **minor diastereomer**:** 169.2, 169.1, 146.0, 144.3, 142.4, 142.2, 142.1, 133.5, 132.5, 132.1, 130.8, 129.6*, 128.5, 127.8, 126.5, 125.4, 121.7, 121.3, 115.2, 114.2, 66.3, 63.2, 63.1, 57.4, 35.4, 35.2, 29.4*, 28.0, 28.0, 14.0. (Note: * indicates overlap of peaks corresponding multiple peaks; ** peaks corresponding to (C=O)CF₃ for the minor diastereomer were not observed at the signal-to-noise ratio of the measurement.)

¹⁹F NMR (471 MHz, CD₂Cl₂) δ -76.09, -76.36, -76.51, -76.53.

HRMS: Exact mass calculated for [C₃₆H₃₇F₆N₃O₆ + H]⁺ requires m/z = 722.2659, found m/z = 736.2661.

Optical: $\alpha_D^{20} = +69.9^\circ$ ($c = 0.5$, MeOH, >99:1 er)

HPLC (Chiralpak® IB connected to Chiralpak® IC column, 55% MeCN/H₂O eluent with 0.5% formic acid buffer, 1.25 mL min⁻¹ flow rate, 25 °C, 265 nm, observed as 1.1:1 dr): major diastereomers $t_R = 22.3$ min, 34.9 min; minor diastereomers $t_R = 23.3$ min, 33.7 min.



Ethyl (4*R*)-4-(*tert*-butyl)-1⁴-methoxy-7-oxo-3⁶,5⁴-bis(2,2,2-trifluoroacetamido)-8-oxa-2-aza-1(1,3)-naphthalena-3,5(1,3)-dibenzenacyclododecaphane-6-carboxylate (4c) was synthesized from **3c** following **Procedure 8**. Crude material was purified by silica chromatography (0→25→80% EtOAc/Hex) to yield the desired product as a beige solid. **4c** is observed as a 2.1:1 mixture of diastereomers in CD₂Cl₂ at 25 °C by ¹H NMR.

Yield: 57% (0.0687 g) using *ent*-**L2**

TLC (30% EtOAc/Hex): $R_f = 0.63, 0.66$.

IR (FT-ATR, cm⁻¹, neat): ν_{\max} 3277, 2953, 2870, 2089, 1717, 1597, 1532, 1387, 1282, 1151, 1032, 906, 752.

¹H NMR (500 MHz, CD₂Cl₂): major diastereomer: δ 10.27 (s, 1H), 8.67 (s, 1H), 8.21 – 8.05 (m, 2H)*, 8.04 (d, $J = 8.5$ Hz, 1H), 7.73 – 7.64 (m, 2H)*, 7.61 – 7.47 (m, 2H)*, 7.44 (d, $J = 8.4$ Hz, 1H), 7.16 (s, 1H), 7.07 (s, 1H), 6.09 (s, 1H), 5.73 (s, 1H), 5.71 (s, 1H), 4.60 (s, 1H), 4.34 – 4.13 (m, 3H)*, 4.07 – 3.98 (m, 1H), 3.84 (s, 3H), 3.71 (s, 1H), 2.69 – 2.39 (m, 2H)*, 1.64 – 1.49 (m, 2H)*, 1.36 – 1.15 (m, 5H)*, 1.05 (s, 9H); minor diastereomer: 10.12 (s, 1H), 8.45 (s, 1H), 8.21 – 8.05 (m, 3H)*, 7.73 – 7.64 (m, 1H)*, 7.61 – 7.47 (m, 3H)*, 7.38 (dd, $J = 8.2, 1.7$ Hz, 1H), 7.31 (s, 1H), 7.25 (s, 1H), 6.11 (s, 1H), 4.62 (s, 1H), 4.34 – 4.13 (m, 3H)*, 4.09 (dt, $J = 9.5, 4.3$ Hz, 1H), 3.82 (s, 1H), 3.81 (s, 3H), 2.69 – 2.39 (m, 2H)*, 1.64 – 1.49 (m, 2H)*, 1.36 – 1.15 (m, 5H)*, 1.06 (s, 9H). (Note: * indicates overlap of peaks corresponding to the major and minor diastereomers.)


¹³C NMR (126 MHz, CD₂Cl₂): major diastereomer: δ 169.9, 169.1, 156.0–154.9 (m, overlapping quartets for ((C=O)CF₃), 148.4, 142.6, 137.5, 135.4, 134.9, 132.6, 131.0, 129.1–129.0*, 127.8, 126.8–126.7*, 126.6, 125.8, 125.7, 123.1, 122.0, 121.1, 116.4 (q, $J = 289.8$ Hz), 116.1 (q, $J = 288.9$ Hz), 113.6, 66.8, 63.5, 63.4, 62.4, 57.8, 35.3, 29.7, 29.4, 29.1, 27.4, 14.1; **minor diastereomer****: δ 169.3, 169.2, 156.0–154.9 (overlapping multiplets for ((C=O)CF₃), 148.7, 142.91, 142.1, 137.2, 134.3, 132.3, 130.7, 129.6, 129.1–129.0*, 127.6, 127.4, 126.8–126.7*, 126.5, 125.9, 125.9, 125.4, 123.2, 121.9, 121.2, 113.2, 66.3, 63.2, 63.2, 62.4, 57.6, 35.3, 29.4, 28.5, 28.5, 27.2, 14.0. (Note: * indicates numerous peaks corresponding to major or minor diastereomers. See page S110 for the spectra.) **Peaks of (C=O)CF₃ for the minor diastereomer were not observed at the signal-to-noise ratio of the measurement.)

¹⁹F NMR (471 MHz, CD₂Cl₂) δ -76.22, -76.52, -76.53, -76.67.

HRMS: Exact mass calculated for [C₄₁H₄₁F₆N₃O₇ + H]⁺ requires $m/z = 802.2921$, found $m/z = 802.2922$.

Optical Rotation: $\alpha_D^{20} = +50.7^\circ$ ($c = 0.5$, MeOH, 99:1 er)

HPLC (Chiralpak® IB column, 55% MeCN/H₂O eluent with 0.5% formic acid buffer, 1.25 mL min⁻¹ flow rate, 25 °C, 265 nm, observed as 1.4:1 dr): major enantiomers $t_R = 50.4$ min, 91.3 min; minor enantiomers $t_R = 52.8$ min, 81.8 min. (Note: Retention times are prone to change due to prolonged run time. Order of elution of diastereomers remains consistent.)



Ethyl (4R)-4-(tert-butyl)-1⁴-methoxy-7-oxo-3⁶,5⁴-bis(2,2,2-trifluoroacetamido)-8-oxa-2-aza-1,3,5(1,3)-tribenzenacyclododecaphane-6-carboxylate (4d) was synthesized from **3d** following **Procedure 8**. Crude material was purified by silica chromatography (0→30→85% EtOAc/Hex) to yield the desired product as a light pink solid. **4d** is observed as a 2.8:1 mixture of diastereomers CD₂Cl₂ at 25 °C by ¹H NMR.

Yield: 49% (0.0553 g) using *ent*-L2.

TLC (30% EtOAc/Hex): $R_f = 0.71$.

IR (FT-ATR, cm⁻¹, neat): ν_{\max} 3321, 2953, 2115, 1717, 1597, 1533, 1500, 1282, 1220, 1152, 1032, 906, 750, 667.

¹H NMR (500 MHz, CD₂Cl₂) **major diastereomer:** δ 10.29 (s, 1H), 8.60 (s, 1H), 7.92 (d, $J = 8.4$ Hz, 1H), 7.73 (d, $J = 8.4$ Hz, 1H), 7.68 – 7.60 (m, 1H)*, 7.48 – 7.35 (m, 1H)*, 7.09 (s, 1H), 7.06 (s, 1H), 6.79 (brs, 2H)*, 6.24 (s, 1H), 5.10 (s, 1H), 4.61 (s, 1H), 4.33 – 4.18 (m, 3H)*, 4.07 – 3.95 (m, 1H)*, 3.78 (s, 3H), 3.64 (s, 1H), 2.54 – 2.43 (m, 1H), 2.32 – 2.21 (m, 1H), 1.64 – 1.46 (m, 2H),* 1.29 – 1.11 (m, 5H),* 1.04 (s, 9H)*; **minor diastereomer:** 9.87 (s, 1H), 8.62 (s, 1H), 8.02 (d, $J = 8.4$ Hz, 1H), 7.68 – 7.60 (m, 1H)*, 7.48 – 7.35 (m, 2H)*, 7.24 (s, 1H), 7.16 (s, 1H), 6.79 (brs, 2H)*, 6.19 (s, 1H), 5.12 (s, 1H), 4.62 (s, 1H), 4.33 – 4.18 (m, 3H)*, 4.07 – 3.95 (m, 1H)*, 3.76 (s, 3H), 3.75 (s, 1H), 2.39 (t, $J = 7.6$ Hz, 2H), 1.64 – 1.46 (m, 2H),* 1.29 – 1.11 (m, 5H),* 1.04 (s, 9H)*. (Note: * indicates overlap of peaks corresponding to major and minor diastereomers)


¹³C NMR (126 MHz, CD₂Cl₂) **major diastereomer:** δ 169.5, 169.2, 156.0–154.9 (m, overlapping quartets), 153.0, 142.6*, 142.4, 138.0, 136.4, 135.3, 132.6, 132.6, 132.2, 129.3, 126.2, 126.0, 125.7, 124.8, 122.4, 118.3, 117.4, 116.4 (q, $J = 283.5$ Hz), 116.3 (q, $J = 284.8$ Hz), 111.7, 66.7, 63.7, 63.3, 57.9, 56.1, 35.4, 30.0, 29.4, 29.0, 25.9, 14.1*; **minor diastereomer**:** δ 169.0, 169.9, 153.0, 142.6*, 142.3, 138.3, 135.9, 132.4, 132.0, 131.8, 128.8, 127.7, 126.6, 126.4, 126.2, 125.4, 121.8, 118.7, 117.3, 111.9, 66.4, 63.3, 63.1, 56.9, 56.1, 35.3, 29.4*, 28.8, 28.1, 26.0, 14.1* (Note: *Indicates overlapping peaks of two diastereomers; **Peaks of (C=O)CF₃, (C=O)CF₃ for the minor diastereomer were not observed at the signal-to-noise ratio of the measurement).

¹⁹F NMR (471 MHz, CD₂Cl₂) δ -75.95, -76.20, -76.46, -76.54.

HRMS: Exact mass calculated for [C₃₇H₃₉F₆N₃O₇ + H]⁺ requires $m/z = 752.2770$, found $m/z = 752.2774$.

Optical Rotation: $\alpha_D^{20} = +64.4^\circ$ ($c = 0.5$, MeOH, 98:2 er)

HPLC (Chiralpak® IB column, 50% MeCN/H₂O eluent with 0.5% formic acid buffer, 1.00 mL min⁻¹ flow rate, 25 °C, 265 nm, observed as 3.0:1 dr): major enantiomer *t_R* = 17.2 min; minor enantiomer *t_R* = 15.4 min. Unresolved pair of major and minor enantiomers *t_R* = 11.7 min.



Ethyl (4*R*)-4-(tert-butyl)-7-oxo-3⁶,5⁴-bis(2,2,2-trifluoroacetamido)-8-oxa-2-aza-1,3,5(1,3)-tribenzenacyclotridecaphane-6-carboxylate (4e) was synthesized from **3e** following **Procedure 8**. Crude material was purified by silica chromatography (0→25→80% EtOAc/Hex) to yield **4e** as a beige solid. **4e** is observed as a 1.9:1 mixture of diastereomers in CD₂Cl₂ at 25 °C by ¹H NMR.

Yield: 23% (0.0254 g)

TLC (30% EtOAc/Hex): *R_f* = 0.76.

IR (FT-ATR, cm⁻¹, neat): *v*_{max} 3324, 2945, 2863, 2125, 1715, 1590, 1531, 1284, 1153, 1026, 907, 732.

¹H NMR (600 MHz, CD₂Cl₂): **major diastereomer:** δ 10.37 (s, 1H), 8.45 (s, 1H), 7.97 (d, *J* = 8.3 Hz, 1H), 7.66 (d, *J* = 8.2 Hz, 1H), 7.44 (s, 1H), 7.31 – 7.28 (m, 2H), 7.24 – 7.15 (m, 2H)*, 6.81 – 6.72 (m, 2H)*, 6.37 (s, 1H), 5.42 (s, 1H), 4.52 (s, 1H), 4.27 – 4.11 (m, 4H), 3.81 (s, 1H), 2.61 (dt, *J* = 12.6, 6.1 Hz, 1H), 2.47 – 2.35 (m, 1H)*, 1.63 – 1.37 (m, 4H)*, 1.29 – 1.08 (m, 5H)*, 1.03 (s, 9H); **minor diastereomer:** 10.21 (s, 1H), 8.54 (s, 1H), 7.93 (d, *J* = 8.5 Hz, 1H), 7.75 (d, *J* = 8.4 Hz, 1H), 7.57 (d, *J* = 7.0 Hz, 1H), 7.36 (d, *J* = 8.2 Hz, 1H), 7.24 – 7.15 (m, 2H)*, 7.07 (s, 1H), 6.81 – 6.72 (m, 2H)*, 6.35 (s, 1H), 5.33 (s, 1H), 4.56 (s, 1H), 4.27 – 4.11 (m, 3H)*, 4.04 (ddd, *J* = 10.7, 6.9, 3.5 Hz, 1H), 3.70 (s, 1H), 2.51 (dt, *J* = 13.9, 7.0 Hz, 1H), 2.47 – 2.35 (m, 1H)*, 1.63 – 1.37 (m, 4H)*, 1.25 (t, *J* = 7.1 Hz, 3H), 1.29 – 1.08 (m, 5H)*, 1.04 (s, 9H). (Note: * indicates overlap of peaks corresponding to major and minor diastereomers)


¹³C NMR (151 MHz, CD₂Cl₂): **major diastereomer:** δ 170.3, 168.4, 156.1–154.8 (m, overlapping quartets of (C=O)CF₃), 144.6, 144.3, 142.0, 141.8, 134.0, 132.8–132.6*, 132.1, 129.7, 129.6, 129.0, 128.5, 126.4–125.3*, 124.6, 122.0, 121.6, 116.5, 116.4 (q, *J* = 288.4 Hz), 116.1 (q, *J* = 288.4 Hz), 114.5, 67.6, 63.2, 63.1, 58.1, 36.0, 35.5, 30.7, 29.3, 28.5, 25.6, 14.0; **minor diastereomer**:** δ 169.4, 169.3, 156.1–154.8 (m, overlapping quartets), 144.8, 144.3, 142.5, 142.3, 135.5, 134.8, 132.8–132.6*, 128.0, 126.4–125.3*, 122.3, 122.1, 117.0, 116.6, 67.4, 63.3, 63.2, 57.7, 36.1, 35.3, 30.3, 29.4, 28.3, 26.1, 14.0. (Note: * indicates numerous peaks corresponding to major or minor diastereomers. See page S116 for the spectra; **peaks of (C=O)CF₃ for the minor diastereomer were not observed at the signal-to-noise ratio of the measurement.)

¹⁹F NMR (471 MHz, CD₂Cl₂) δ -76.08, -76.28, -76.54.

HRMS: Exact mass calculated for [C₃₇H₃₉F₆N₃O₆ + H]⁺ requires *m/z* = 736.2821, found *m/z* = 736.2823.

Optical Rotation: $\alpha_D^{20} = +9.8^\circ$ ($c = 0.5$, MeOH, 99:1 er)

HPLC: (Chiralpak® IB column, 55% MeCN/H₂O eluent, 1.00 mL min⁻¹ flow rate, 25 °C, 265 nm, observed as 2.1:1 dr): major enantiomers $t_R = 25.6$ min, 31.9 min; minor enantiomers $t_R = 33.5$ min, 35.9 min.



Ethyl (4R)-4-(tert-butyl)-1⁵-hydroxy-7-oxo-3⁶,5⁴-bis(2,2,2-trifluoroacetamido)-8-oxa-2-aza-1,3,5(1,3)-tribenzenacyclododecaphane-6-carboxylate (4f) was synthesized from **3f** following **Procedure 8**. Crude material was purified by silica chromatography (0→25→80% EtOAc/Hex) to yield **4f** as an off-white solid. **4f** is observed as a 2.5:1 mixture of diastereomers in CD₂Cl₂ at 25 °C by ¹H NMR.

Yield: 43% (0.0477 g) using *ent*-L2

TLC (30% EtOAc/Hex): $R_f = 0.33$.

IR (FT-ATR, cm⁻¹, neat): ν_{\max} 3344, 3021, 2953, 2868, 2118, 1715, 1597, 1533, 1282, 1215, 1153, 1028, 836, 750.

¹H NMR (600 MHz, CD₂Cl₂): **major diastereomer:** δ 10.29 (s, 1H), 8.69 (s, 1H), 8.08 (d, $J = 8.5$ Hz, 1H), 7.72 (d, $J = 8.5$ Hz, 1H), 7.69 – 7.63 (m, 1H)*, 7.47 (d, $J = 8.5$ Hz, 1H), 7.20 (s, 1H)*, 7.07 (s, 1H), 6.25 (s, 1H)*, 6.13 (s, 1H)*, 5.57 (s, 1H)*, 5.17 (s, 1H), 5.00 (s, 1H)*, 4.59 (s, 1H), 4.35 – 4.12 (m, 3H)*, 3.96 (ddd, $J = 11.0, 7.3, 3.9$ Hz, 2H), 3.69 (s, 1H), 2.29 – 2.17 (m, 2H)*, 1.53 – 1.36 (m, 2H)*, 1.28 (t, $J = 7.1$ Hz, 3H), 1.18 – 1.07 (m, 2H)*, 1.04 (s, 9H)*; **minor diastereomer:** δ 10.06 (s, 1H), 8.62 (s, 1H), 8.16 (d, $J = 8.5$ Hz, 1H), 7.69 – 7.63 (m, 1H)*, 7.51 (d, $J = 8.5$ Hz, 1H), 7.37 (d, $J = 8.3$ Hz, 1H), 7.27 (s, 1H), 7.20 (s, 1H)*, 6.25 (s, 1H)*, 6.13 (s, 1H)*, 5.57 (s, 1H)*, 5.26 (s, 1H), 5.00 (s, 1H)*, 4.61 (s, 1H), 4.35 – 4.12 (m, 3H)*, 4.03 (dt, $J = 10.8, 5.2$ Hz, 1H), 3.80 (s, 1H), 2.29 – 2.17 (m, 2H)*, 1.53 – 1.36 (m, 2H)*, 1.23 (t, $J = 7.2$ Hz, 3H), 1.18 – 1.07 (m, 2H)*, 1.04 (s, 9H)*. (Note: *indicates overlap of major and minor diastereomers)


¹³C NMR (151 MHz, CD₂Cl₂): **major diastereomer:** δ 169.8, 169.1, 157.2*, 156.2–154.7 (m, overlapping quartets of (C=O)CF₃), 147.5, 145.7, 142.5, 142.1, 135.3, 133.7, 132.5, 130.2, 129.2, 128.9, 127.1, 126.4, 125.6, 121.5, 116.4 (q, $J = 288.41$ Hz), 116.1 (q, $J = 289.92$ Hz), 108.4, 107.0, 102.2, 66.6, 63.5, 63.4, 57.8, 35.9, 35.3, 29.4*, 28.6, 27.9, 14.0; **minor diastereomer**:** δ 169.3, 169.2, 157.2*, 147.4, 145.7, 142.4, 142.2, 133.3, 132.6, 132.4, 132.2, 130.9, 128.8, 128.0, 126.5, 125.4, 121.3, 108.9, 106.6, 101.7, 66.3, 63.3, 63.1, 57.4, 35.4, 35.2, 29.4*, 28.0, 27.8, 14.0. (Note: *indicates overlapping peaks of major and minor diastereomers; **peaks of (C=O)CF₃, (C=O)CF₃ for the minor diastereomer were not observed at the signal-to-noise ratio of the measurement).

¹⁹F NMR (471 MHz, CD₂Cl₂) δ -76.11, -76.37, -76.51, -76.54.

HRMS: Exact mass calculated for [C₃₆H₃₇F₆N₃O₇ + H]⁺ requires $m/z = 738.2608$, found $m/z = 738.2599$.

Optical Rotation: $\alpha_D^{20} = +91.0^\circ$ ($c = 0.5$, MeOH, >99:1 er)

HPLC (Chiralpak® IB column, 55% MeCN/H₂O eluent with 0.5% formic acid buffer, 1.20 mL min⁻¹ flow rate, 25 °C, 265 nm, observed as 1.8:1 dr): major enantiomer t_R = 8.4 min; minor enantiomer t_R = 8.9 min. Unresolved pair of major and minor enantiomers t_R = 14.7 min.



Ethyl (4*R*)-1⁵-amino-4-(*tert*-butyl)-7-oxo-3⁶,5⁴-bis(2,2,2-trifluoroacetamido)-2,8-dioxa-1,3,5(1,3)-tribenzenacyclododecaphane-6-carboxylate (5f) was synthesized from **3f** following **Procedure 8**. Crude material was purified by silica chromatography (0→45→80% EtOAc/Hex eluent) to yield the desired product **5f** as a white solid. **5f** is observed as a 4.3:1 mixture of diastereomers CD₂Cl₂ at 25 °C by ¹H NMR.

Yield: 11% (0.0126 g) with **L3**

TLC (40% EtOAc/Hex): R_f = 0.53.

IR (FT-ATR, cm⁻¹, neat): ν_{\max} 3389, 3288, 2953, 2868, 2126, 1727, 1590, 1535, 1289, 1159, 1030, 835.

¹H NMR (500 MHz, CD₂Cl₂): **major diastereomer:** δ 10.28 (s, 1H), 8.43 (s, 1H), 8.30 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.42–7.40 (m, 1H)*, 7.30 (s, 1H), 7.06 (s, 1H)*, 6.90 (s, 1H), 6.39 (s, 1H), 6.24 (s, 1H), 4.60 (s, 1H), 4.34–4.17 (m, 3H)*, 3.96 (ddd, J = 11.1, 7.3, 3.9 Hz, 1H), 3.82 (brs, 2H), 3.66 (s, 1H), 2.29–2.23 (m, 2H)*, 1.52–1.45 (m, 2H)*, 1.29 (t, J = 7.1 Hz, 3H), 1.17–1.10 (m, 2H)*, 1.04 (s, 9H); **minor diastereomer:** 9.87 (s, 1H), 8.36 (s, 1H), 8.28 (d, J = 8.6 Hz, 1H), 7.65 (d, J = 8.3 Hz, 1H), 7.42–7.40 (m, 1H)*, 7.37 (d, J = 8.4 Hz, 1H), 7.06 (s, 1H)*, 6.36 (s, 1H), 6.23 (s, 1H), 4.65 (s, 1H), 4.34–4.17 (m, 3H)*, 4.07–4.02 (m, 1H), 3.82 (brs, 2H), 3.77 (s, 1H), 2.34–2.31 (m, 1H), 2.29–2.23 (m, 1H)*, 1.52–1.45 (m, 2H)*, 1.25 (t, J = 7.1 Hz, 3H), 1.17–1.10 (m, 2H)*, 1.03 (s, 9H). (*indicates overlap of peaks corresponding to the major and minor diastereomers.)



¹³C NMR (126 MHz, CD₂Cl₂): **major diastereomer:** δ 169.8, 168.9, 158.2, 155.5 (q, J = 36.5 Hz), 154.7 (q, J = 36.5 Hz), 148.8, 146.0, 145.8, 142.3, 141.6, 135.2*, 132.6, 129.3, 126.3, 125.1, 125.6, 124.9, 121.5, 120.8, 116.4 (q, J = 287.9 Hz), 116.1 (q, J = 288.5 Hz), 111.1, 105.7, 103.2, 66.4, 63.5, 63.4, 57.8, 35.7, 35.4, 29.4, 28.6, 27.7, 14.1*; **minor diastereomer**:** δ 169.3, 168.8, 158.3, 148.9, 145.7, 142.2, 142.0, 135.2*, 132.4, 132.1, 132.0, 126.7, 126.5, 126.0, 125.5, 121.7, 121.1, 111.5, 105.6, 102.5, 66.1, 63.3, 63.2, 56.9, 35.3, 35.3, 29.3, 27.8, 27.4, 14.1*.


(Note: *indicates a peak corresponding to both the major and minor diastereomers; **peaks of (C=O)CF₃, (C=O)CF₃ for the minor diastereomer were not observed at the signal-to-noise ratio of the measurement)

¹⁹F NMR (471 MHz, CD₂Cl₂) δ -76.26, -76.36, -76.48, -76.57.

Optical Rotation: α_D^{20} = +25.9° (c = 0.3, MeOH, 93:7 er)



HRMS: Exact mass calculated for $[\text{C}_{36}\text{H}_{37}\text{F}_6\text{N}_3\text{O}_7 + \text{H}]^+$ requires $m/z = 738.2609$, found $m/z = 738.2593$.









4a
(¹H NMR, CD₂Cl₂, 471 MHz)

-76.17
-76.52
-76.52
-76.54




















4b
(¹⁹F NMR, CD₂Cl₂, 471 MHz)








**4c**¹H NMR, CD₂Cl₂, 500 MHz**4c**¹³C NMR, CD₂Cl₂, 126 MHz














4d
(^{19}F NMR, CD_2Cl_2 , 471 MHz)
















4e
(¹⁹F NMR, CD₂Cl₂, 471 MHz)








**4f**¹H NMR, CD₂Cl₂, 600 MHz)**4f**¹³C NMR, CD₂Cl₂, 151 MHz)






4f
(¹⁹F NMR, CD₂Cl₂, 471 MHz)

76.11
76.37
76.51
76.54












5f
(¹⁹F NMR, CD₂Cl₂, 471 MHz)










12.1 HPLC Traces of Macrocyclic Compounds (4a-f)






4a

Chiralpak IB


55% MeCN/H₂O with 0.5% formic acid, 1.250 mL/min, 25 °C, 265 nm


**4b**

Chiralpak IB connected to Chiralpak IC
55% MeCN/H₂O with 0.5% formic acid, 1.250 mL/min, 25 °C, 265 nm


**L3 (achiral ligand)**


DAD1 B, Sig=265,4 Ref=360,100 (JHWH-I-168 2020-10-07 13-23-48\015-0101.D)



**4c**





Chiralpak IB


55% MeCN/H₂O with 0.5% formic acid, 1.250 mL/min, 25 °C, 265 nm



Chiralpak IB

50% MeCN/H₂O with 0.5% formic acid, 1.000 mL/min, 25 °C, 265 nm.




**4e**

Chiralpak IB

55% MeCN/H₂O with 0.5% formic acid, 1.000 mL/min, 25 °C, 265 nm


Analytical standard (observed as 2.1:1 dr)

DAD1 B, Sig=265,4 Ref=360,100 (JH/JH-I-168 2020-08-28 15-50-09/002-0101.D)




ent-L2 (matched ligand)

DAD1 B, Sig=265,4 Ref=360,100 (JH/JH-I-168 2020-08-28 17-48-13/005-0301.D)




L2 (mismatched ligand)


DAD1 B, Sig=265,4 Ref=360,100 (JH/JH-I-168 2020-08-29 09-33-05/004-0201.D)








L3 (achiral ligand)

DAD1 B, Sig=265,4 Ref=360,100 (JH/JH-I-168 2020-08-29 09-33-05/003-0101.D)







Chiralpak IB
55% MeCN/H₂O with 0.5% formic acid
1.200 mL/min, 25 °C, 265 nm






13. Product Distribution: Macrocyclization of 3a, 3b and 3c (UPLC-MS Traces)




14. Product Distribution: Macrocyclization of Aminophenol 3f (UPLC-MS Traces)



Reaction executed following **Procedure 8**.





15. NMR Studies


15.1 VT-NMR Experiments^{a,b,c}

Figure S2. ¹H NMR spectra of **4a** and **4a'** (H₁) in DMSO-*d*₆ from 25–120 °C. a) VT-NMR experiments were performed on a Agilent 500 MHz spectrometer in DMSO-*d*₆. b) No convergence is observed between two sets of peaks corresponding to H₁. Change in ratio between two diastereomers is observed.










Figure S3. Full ^1H NMR spectra of **4a** and **4a'** in $\text{DMSO-}d_6$ from 25–120 $^\circ\text{C}$. a) VT-NMR experiments were performed on Agilent 500 MHz spectrometer in $\text{DMSO-}d_6$. c) No significant decomposition is observed.

15.2 Deuterium Incorporation in Methanol- d_4 :Figure S4. Full ^1H NMR spectrum of **4a** and **4a'** in methanol- d_4 .

15.3 ^1H NMR Spectra of 4a in Different NMR Solvents





16. Crystallographic Data

Experimental

Low-temperature diffraction data (ω -scans) were collected on a Rigaku MicroMax-007HF diffractometer coupled to a Saturn994+ CCD detector with Cu K α ($\lambda = 1.54178 \text{ \AA}$) for the structure of 4a. The diffraction images were processed and scaled using Rigaku Oxford Diffraction software (CrysAlisPro; Rigaku OD: The Woodlands, TX, 2015). The structure was solved with SHELXT and was refined against F^2 on all data by full-matrix least squares with SHELXL (Sheldrick, G. M. Acta Cryst. 2008, A64, 112–122). All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included in the model at geometrically calculated positions and refined using a riding model. The isotropic displacement parameters of all hydrogen atoms were fixed to 1.2 times the U value of the atoms to which they are linked (1.5 times for methyl groups). There are several sites for disorder in this structure. The CF₃ groups are disordered over two positions. All chemically equivalent 1,2 and 1,3 distances in the disordered models were restrained to be similar. Their atomic displacement parameters were also restrained to be similar. Two of the esters were also disordered over two positions. The disordered C-O and C-C distances were restrained to be similar. The full numbering scheme of compound 4a can be found in the full details of the X-ray structure determination (CIF), which is included as Supporting Information. CCDC number 2081828 (**4a**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif.

A Bayesian statistical analysis of the Bijvoet pairs suggest the model reported here is the true model, with an exceedingly small probability of a model with the opposite chirality or a racemic twin. This analysis was calculated with the PLATON software package (A.L.Spek, Acta Cryst. 2009, D65, 148-155.).

Model as presented in the CIF

Space Group	P2 ₁
Wavelength	1.54184
Flack x	-0.05(8)
Parsons z ..	-0.03(7)

Bayesian Statistics

Student_T v	12
Select Pairs	6773
θ _Min	3.11°
θ _Max	66.59°
P2(true)	1.000
P3(true)	1.000
P3(rac-twin)	0.7E-13
P3(false)	0.2E-49
G	1.0501

G (su) 0.1347
 Hooft y -0.03(7)

Inverted model

Space Group P21
 Wavelength 1.54184
 Flack x 1.05(8)
 Parsons z .. 1.03(7)

Bayesian Statistics

Student_T v 12
 Select Pairs 6773
 θ _Min 3.11
 θ _Max 66.59
 P2(true) 0.3E-49
 P3(true) 0.3E-49
 P3(rac-twin) 0.8E-13
 P3(false) 1.000
 G -1.0481
 G (su) 0.1347
 Hooft y 1.02(7)




Figure 1. The complete numbering scheme of 4a with 50% thermal ellipsoid probability levels. The hydrogen atoms are shown as circles for clarity.

Table 1. Crystal data and structure refinement for 4a.

Identification code	007b-21047
Empirical formula	C ₄₃ H ₄₅ F ₆ N ₃ O ₆
Formula weight	813.82
Temperature	93(2) K
Wavelength	1.54184 Å
Crystal system	Monoclinic
Space group	P2 ₁
Unit cell dimensions	a = 9.83610(10) Å α = 90°.
	b = 22.6576(3) Å β = 102.3820(10)°.
	c = 18.7122(2) Å γ = 90°.
Volume	4073.24(8) Å ³
Z	4
Density (calculated)	1.327 Mg/m ³
Absorption coefficient	0.906 mm ⁻¹
F(000)	1704
Crystal size	0.200 x 0.200 x 0.020 mm ³
Crystal color and habit	colorless plate
Diffraction	Rigaku Saturn 944+ CCD
Theta range for data collection	2.417 to 66.593°.
Index ranges	-11 ≤ h ≤ 11, -26 ≤ k ≤ 26, -22 ≤ l ≤ 22
Reflections collected	123574
Independent reflections	14178 [R(int) = 0.0925]
Observed reflections (I > 2σ(I))	11671
Completeness to theta = 66.593°	100.0 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	1.00000 and 0.90494
Solution method	SHELXT-2014/5 (Sheldrick, 2014)
Refinement method	SHELXL-2014/7 (Sheldrick, 2014)
Data / restraints / parameters	14178 / 199 / 1129
Goodness-of-fit on F ²	1.015
Final R indices [I > 2σ(I)]	R1 = 0.0559, wR2 = 0.1356
R indices (all data)	R1 = 0.0723, wR2 = 0.1474
Absolute structure parameter	-0.05(8)
Largest diff. peak and hole	0.554 and -0.463 e.Å ⁻³

References

1. G. R. Fulmer *et al.*, NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist. *Organometallics* **29**, 2176–2179 (2010).
2. a) B. Kim, A. J. Chinn, D. R. Fandrick, C. H. Senanayake, R. A. Singer, S. J. Miller, Distal Stereocontrol Using Guanidinylated Peptides as Multifunctional Ligands: Desymmetrization of Diarylmethanes via Ullman Cross-Coupling. *J. Am. Chem. Soc.* **138**, 7939–7945 (2016). b) A. J. Chinn, B. Kim, Y. Kwon, S. J. Miller, Enantioselective Intermolecular C–O Bond Formation in the Desymmetrization of Diarylmethines Employing a Guanidinylated Peptide-Based Catalyst. *J. Am. Chem. Soc.* **139**, 18107–18114 (2017). c) Y. Kwon, A. J. Chinn, B. Kim, S. J. Miller, Divergent Control of Point and Axial Stereogenicity: Catalytic Enantioselective C–N Bond-Forming Cross-Coupling and Catalyst-Controlled Atroposelective Cyclodehydration. *Angew. Chem. Int. Ed.* **57**, 6251–6255 (2018).
3. E. Moreau *et al.*, Optimized *N*-Phenyl-*N'*-(2-chloroethyl)ureas as Potential Antineoplastic Agents: Synthesis and Growth Inhibition Activity. *Bioorg. Med. Chem.* **13**, 6703–6712 (2005).
4. F. A. Abulwerdi *et al.*, 3-Substituted-*N*-(4-Hydroxynaphthalen-1-yl)arylsulfonamides as a Novel Class of Selective Mcl-1 Inhibitors: Structure-Based Design, Synthesis, SAR, and Biological Evaluation. *J. Med. Chem.* **57**, 4111–4133 (2014).
5. C. Holt, G. Alachouzou, A. J. Frontier, Leveraging the Halo-Nazarov Cyclization for the Chemodivergent Assembly of Functionalized Haloindenes and Indanones. *J. Am. Chem. Soc.* **141**, 5461–5469 (2019).
6. B. R. Ambler, S. Peddi, R. A. Altman, Ligand-Controlled Regioselective Copper-Catalyzed Trifluoromethylation To Generate (Trifluoromethyl)allenes. *Org. Lett.* **17**, 2506–2509 (2015).
7. P. Patel, C. V. Ramana, Divergent Pd(II) and Au(III) mediated nitroalkynol cycloisomerizations. *Org. Biomol. Chem.* **9**, 7327–7334 (2011).